Prosthetic heart valve having tubular seal

Information

  • Patent Grant
  • 10201417
  • Patent Number
    10,201,417
  • Date Filed
    Thursday, January 28, 2016
    8 years ago
  • Date Issued
    Tuesday, February 12, 2019
    5 years ago
Abstract
A tubular seal for a prosthetic heart valve includes an elastomeric polymer matrix and a plurality of non-elastic fibers retained within the matrix. The non-elastic fibers can be arranged in the elastomeric polymer matrix to allow the tubular seal to stretch in axial and radial directions.
Description
FIELD

This document provides prosthetic heart valves having a tubular seal.


BACKGROUND

The human heart contains four valves: a tricuspid valve, a pulmonic valve, a mitral valve and an aortic valve. The main purpose of the valves is to maintain unimpeded forward flow through the heart and into the major blood vessels connected to the heart, for example, the pulmonary artery and the aorta. As a result of a number of disease processes, both acquired and congenital, any one of the four heart valves may malfunction and result in either stenosis (impeded forward flow) and/or backward flow (regurgitation). Either process burdens the heart and may lead to serious problems, for example, heart failure. Various procedures for fixing or replacing defective heart valves are known in the art. In some cases, artificial heart valves can be implanted in the heart of a patient to replace a diseased or damaged heart valve with a prosthetic equivalent.


Prosthetic heart valves can have a variety of designs. Two major types of prosthetic heart valves include mechanical heart valves and bioprosthetic heart valves. Mechanical heart valves can be made of synthetic materials, such as plastics or metals, while bioprosthetic heart valves can be made of biologic tissue mounted on a fabric covered plastic or metal frame. Bioprosthetic heart valves can include animal tissue, such as porcine or bovine tissue, that has been chemically treated to make the valve suitable for implantation in a human. Bioprosthetic valves do not generally require a patient to undergo anticoagulant therapy, which is typically required when using mechanical valves. As such, there is a need to further improve the design of bioprosthetic valves to retain its functionality during the life of the patient and minimize stenosis and regurgitation.


SUMMARY

Prosthetic heart valves provided herein can have a structure adapted to retain functionality during the life of the patient and to minimize stenosis and regurgitation by having an improved connection between different parts of the prosthetic heart valve.


In Example 1, a tubular seal for a prosthetic heart valve includes an elastomeric polymer matrix and a plurality of non-elastic fibers retained within the matrix. The non-elastic fibers can be arranged in the elastomeric polymer matrix to allow the tubular seal to stretch in axial and radial directions.


In Example 2, the tubular seal of Example 1, wherein the non-elastic fibers are part of a fabric.


In Example 3, the tubular seal of Example 2, wherein the fabric is a woven fabric.


In Example 4, the tubular seal of Example 3, wherein the woven fabric includes fibers in a warp direction and fibers in a waft direction, wherein the fibers in both the warp direction and the waft direction are angled with respect to a central axis of the tubular seal.


In Example 5, the tubular seal of Example 3, wherein the fibers in both the warp direction and the waft direct are angled at an angle of between 5 degrees and 70 degrees with respect to the central axis of the tubular seal.


In Example 6, the tubular seal of one of the preceding examples, wherein the non-elastic fibers are uniformly dispersed throughout the elastomeric polymer matrix.


In Example 7, the tubular seal of one of the preceding examples, wherein the tubular seal has a substantially uniform thickness.


In Example 8, the tubular seal of Examples 2-5, wherein the tubular seal comprises an outflow end region and an inflow end region, the inflow end region being a portion of the tubular seal comprising the fabric, wherein the fabric has a non-linear edge defining the interface between the inflow end region and the outflow end region.


In Example 9, the tubular seal of Example 8, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.


In Example 10, the tubular seal of Example 8 or 9, wherein the inflow end region comprises a first substantially uniform thickness and the outflow end region comprises median thickness that is less than the first substantially uniform thickness.


In Example 11, the tubular seal of Examples 8-10, wherein the outflow end region comprises a plurality of grommets.


In Example 12, the tubular seal of one of the preceding examples, wherein the non-elastic fibers are retained within an inflow end portion of the elastomeric polymer matrix, the inflow end portion of the tubular seal are secured to the bottom edges of the plurality of leaflets, and the fabric comprises a non-linear edge within the elastomeric polymer matrix.


In Example 13, the tubular seal of Example 12, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.


In Example 14, the tubular seal of one of the preceding examples, wherein the non-elastic fibers comprise a polyester.


In Example 15, the tubular seal of one of the preceding examples further comprising wherein an expandable tubular member and a plurality of leaflets secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member and a free edge at a blood outflow end of the expandable tubular member.


In Example 16, a prosthetic heart valve includes an expandable tubular member, a plurality of leaflets and a tubular seal. The plurality of leaflets can be secured together along side edges and retained within the expandable tubular member. Each leaflet can have a bottom edge at a blood inflow end of the expandable tubular member and a free edge at a blood outflow end of the expandable tubular member. The tubular seal can be secured to the bottom edge of each leaflet and along an outer portion of the expandable tubular member, wherein the tubular seal includes an elastomeric polymer matrix and a plurality of non-elastic fibers retained within the matrix, and wherein the non-elastic fibers are arranged in the elastomeric polymer matrix to allow the tubular seal to stretch in axial and radial directions.


In Example 17, the prosthetic heart valve of Example 16, wherein the non-elastic fibers are part of a fabric.


In Example 18, the prosthetic heart valve of Example 17, wherein the fabric is a woven fabric.


In Example 19, the prosthetic heart valve of Example 18, wherein the woven fabric comprises fibers in a warp direction and fibers in a waft direction, wherein the fibers in both the warp direction and the waft direction are angled with respect to a central axis of the tubular seal.


In Example 20, the prosthetic heart valve of Example 18, wherein the fibers in both the warp direction and the waft direct are angled at an angle of between 5 degrees and 70 degrees with respect to the central axis of the tubular seal.


In Example 21, the prosthetic heart valve of Example 16, wherein the non-elastic fibers are uniformly dispersed throughout the elastomeric polymer matrix.


In Example 22, the prosthetic heart valve of Example 21, wherein the tubular seal has a substantially uniform thickness.


In Example 23, the prosthetic heart valve of Example 21, wherein the tubular seal comprises an outflow end region and an inflow end region, the inflow end region being a portion of the tubular seal comprising the fabric, wherein the fabric has a non-linear edge defining the interface between the inflow end region and the outflow end region.


In Example 24, the prosthetic heart valve of Example 23, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.


In Example 25, the prosthetic heart valve of Example 23, wherein the inflow end region comprises a first substantially uniform thickness and the outflow end region comprises median thickness that is less than the first substantially uniform thickness.


In Example 26, the prosthetic heart valve of Example 23, wherein the outflow end region comprises a plurality of grommets.


In Example 27, the prosthetic heart valve of Example 16, wherein the tubular seal has a thickness range from about 30 microns to about 75 microns.


In Example 28, the prosthetic heart valve of Example 16, wherein the tubular seal has a thickness range from about 50 microns to about 120 microns.


In Example 29, a prosthetic heart valve includes an expandable tubular member, a plurality of leaflets and a tubular seal. The plurality of leaflets can be secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member and a free edge at a blood outflow end of the expandable tubular member. The tubular seal can include an elastomeric polymer matrix and a fabric can include a plurality of non-elastic fibers retained within an inflow end portion of the elastomeric polymer matrix. The inflow end portion of the tubular seal can be secured to the bottom edges of the plurality of leaflets, wherein the fabric includes a non-linear edge within the elastomeric polymer matrix.


In Example 30, the prosthetic heart valve of Example 29, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.


In Example 31, the prosthetic heart valve of Example 29, wherein the non-elastic fibers comprise a polyester.


In Example 32, the prosthetic heart valve of Example 29, wherein the elastomeric polymer matrix comprises a first material composition and a second material composition, wherein the first material composition is different than the second material composition.


In Example 33, the prosthetic heart valve of Example 29, wherein the elastomeric polymer matrix comprises a polymer selected from polycarbonates, polyurethanes, silicones, and combinations thereof.


In Example 34, the prosthetic heart valve of Example 29, wherein the elastomeric polymer matrix comprises a polymer having a hardness ranging from 75 Shore A to 75 Shore D.


In Example 35, a prosthetic heart valve includes an expandable tubular member, a plurality of leaflets and a tubular seal. The plurality of leaflets can be secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member. The tubular seal can include a polymer matrix and a fabric retained within an inflow end portion of the polymer matrix, wherein the fabric includes a non-linear edge within the polymer matrix.


Prosthetic heart valves provided herein can additionally have a reduced unexpanded profile. In some cases, prosthetic heart valves provided herein include a plurality of anchor elements. In some cases, anchor elements can be secured to an expandable tubular member. In some cases, the expandable tubular member can be a braided stent. In some cases, prosthetic heart valves provided herein include three or more leaflets. In some cases, the leaflets can have a body portion and sleeve portions one or both sides. In some cases, sides of the body portions can be secured together and sleeve portions secured to anchor elements (e.g., anchor elements attached to a braided stent). In some cases, prosthetic heart valves provided herein can include a tubular seal. In some cases, the tubular seal can be secured to bottom edges of body portions of the leaflets. In some cases, the seal can be secured to a blood inlet side of an expandable member.


The details of one or more embodiments of the invention are set forth in the accompanying drawings and the description below. Other features, objects, and advantages of the invention will be apparent from the description and drawings, and from the claims.





DESCRIPTION OF DRAWINGS


FIGS. 1A-1H illustrate an exemplary prosthetic heart valve and an exemplary deployment device provided herein. FIG. 1A is a perspective view of the heart valve connected to the deployment device. FIG. 1B is a side view of the exemplary prosthetic heart valve. FIGS. 1C-1H illustrate how the exemplary heart valve provided herein can be delivered by the deployment device.



FIGS. 2A-2C illustrates an exemplary leaflet, which can be used in prosthetic heart valves provided herein. FIG. 2A illustrates a rounded notch in a leaflet where a leaflet can be secured to an adjacent leaflet. FIGS. 2B and 2C illustrate a portion of an exemplary leaflet for prosthetic heart valves. FIG. 2B depicts the rounded notch in an armpit of a leaflet. FIG. 2C depicts attachment elements in the armpit of the leaflet.



FIG. 3 illustrates another exemplary leaflet, which can be used in prosthetic heart valves provided herein. FIG. 3 depicts apertures in a body of the exemplary leaflet.



FIGS. 4A-4G illustrate how adjacent leaflets can be stitched together in prosthetic heart valves provided herein.



FIGS. 5A-5C illustrate a cross stich provided herein for connecting a seal to a braided stent in an exemplary prosthetic heart valve provided herein. FIG. 5A shows a front view of a seal having apertures and stitch patterns used for securing the seal to the braided stent. FIG. 5B depicts a close up view of a cross stitch and a portion of a circumferential stitch used for securing the seal to the braided stent. FIG. 5C depicts a cross-sectional view showing the cross stitch and a portion of the circumferential stitch.



FIG. 6 depicts an apparatus that can be used to form a tubular seal provided herein.



FIGS. 7A-7E depict exemplary tubular seals having a fabric positioned within a matrix that can be used in a prosthetic heart valve provided herein.





Like reference symbols in the various drawings indicate like elements.


DETAILED DESCRIPTION


FIGS. 1A and 1B illustrate an exemplary prosthetic heart valve 100 provided herein. FIGS. 1C-1H depict how prosthetic heart valve 100 is deployed. FIG. 1A is a perspective view of prosthetic heart valve 100 connected to a deployment device 190.



FIG. 1B is a side view of prosthetic heart valve 100. As shown, prosthetic heart valve 100 includes an expandable member 110, three leaflets 200, three anchor elements 120 that secure sleeve portions 216 of leaflets 200 to expandable member 110, and a tubular seal 130 secured around a blood inflow end of prosthetic heart valve 100. Anchor elements 120 can include post leg compression elements 122 and clamping support structures 126 adapted to provide support along opposite sides of the sleeve portions 216. Expandable member 110 in FIGS. 1A-1D is a braided stent, which is adapted to transition between a restricted state having a smaller diameter and an expanded state having a larger diameter. Expandable member 110 can be self-expanding, mechanically expanded, or a combination thereof.



FIGS. 1C-1H depict how an exemplary heart valve delivery system can deliver the prosthetic heart valve provided herein. As shown in FIGS. 1C-1H, prosthetic heart valve 100 can be deployed using a heart valve delivery system 180. System 180 can include a sheath 182 for retaining the prosthetic heart valve 100 with the expandable member 110 in a restricted state. As discussed above, tubular seals provided herein can have a uniform thickness or a thickness that has a non-linear interface between an inflow end portion and an outflow end portion to provide a transition zone between a thinner outflow end portion to the thicker inflow end portion to facilitate loading of prosthetic heart valve 100 into sheath 182. For example, a substantially uniform thickness or a transition zone can reduce the probability for sections of the tubular seal to catch on an outer rim of sheath 182 during loading of prosthetic heart valve 100 in a restricted state. Additionally, tubular seals provided herein can allow for radial and/or axial expansion of the tubular seal in portions including non-elastic fibers, accordingly, a tubular seal used in prosthetic heart valves provided herein can have a non-expanded diameter that expands to the predetermined outer diameter of the expandable member and that stretches to an axially elongated but radially restricted configuration when the prosthetic heart valve is in a restricted state to further reduce the profile of the prosthetic heart valve within the sheath.


Within sheath 182, anchor elements 120 (FIGS. 1A and 1B) can be connected to pushing prongs 192 and a pull line 194 can be connected to a nose cap 196, or end cap, which is positioned at the end of the sheath 182. As shown in FIG. 1A, the pull line 194 can extend through expandable member 110 and through the valve opening between the leaflets 200. As shown by FIGS. 1D-1H, once a distal end of sheath 182 is delivered through the circulatory system to an appropriate location (e.g., within the heart), prosthetic heart valve 100 can be deployed. By advancing pushing prongs 192 and pull line 194 relative to sheath 182, prosthetic heart valve 100 can be pushed out of the sheath 182. In some cases, expandable member 110 can self-expand upon exiting sheath 182. In some cases, expandable member 110 can self-expand to a first intermediate diameter, and system 180 can mechanically expand expandable member 110 to a larger deployment diameter. For example, anchor elements 120 can include a locking mechanism to clip a portion of expandable member when the expandable member 110 is expanded to a predetermined locking diameter. In some cases, system 180 can mechanically expand expandable member 110 to a predetermined locking diameter. In some cases, system 180 can compress expandable member 110 between pushing prongs 192 and nose cap 196 by moving pull line 194 relative to pushing prongs 192. The predetermined locking diameter can be adapted to set the diameter of the prosthetic heart valve 100 during implantation. After prosthetic heart valve 100 is set, system 180 can move pull line 194 and nose cap 196 relative to pushing prongs 192 to move the end cap through the opening between leaflets 200 in prosthetic heart valve 100. Pushing prongs 192 can then be retracted from anchor elements 120 and retracted into sheath 182. In some cases, pushing prongs 192 can include a shape member material adapted to help radially expand expandable member 110 as the expandable member 110 exits sheath 182. A control handle 188 can be used to control the relative movements of sheath 182, pushing prongs 192, and pull wire 194. Prosthetic heart valves provided herein can be adapted to mitigate damage that might otherwise occur to valves during delivery and implantation.


In some cases, one or more radiopaque markers can be secured to prosthetic heart valves provided herein. As shown in FIGS. 1A and 1B, expandable member 110 includes a radiopaque marker 112. Any suitable radiopaque material (such as platinum, palladium, gold, tantalum, or alloys thereof) can be used as the radiopaque material in radiopaque marker 112. One or more radiopaque markers can be used with an imaging system to help a physician ensure that a valve is set in an appropriate location. In some cases, prosthetic heart valves provided herein include at least three radiopaque markers.


As shown in FIG. 1A, prosthetic heart valve 100 can include a plurality of leaflets 200. In some cases, as shown, prosthetic heart valve 100 includes three leaflets 200. In some cases, prosthetic heart valves provided herein can have any suitable number of leaflets, such as two, three, four, five, or more leaflets. In some cases, leaflets 200 are secured to one another. In some cases, leaflets 200 can be secured to one another via a plurality of sutures. Leaflets 200 can be sutured along side edges of a body portion of each leaflet. In some cases, prosthetic heart valves provide herein can include a single line of sutures, which can be adapted to minimize leaks, minimize the width of a seam, and/or minimize the profile of a replacement heart valve during percutaneous insertion. In some cases, prosthetic heart valves provide herein can include multiple lines of sutures.


Expandable member 110 can have any suitable structure, arrangement, or material. In some cases, expandable member 110 can include a braided wire stent. For example, U.S. Publication Number 2005/0143809, titled, “Methods and Apparatus for Endovascularly Replacing a Heart Valve,” and filed on Nov. 5, 2004, which is herein incorporated by reference for its disclosure of possible structures and materials for a braided wire stent, discloses a braided wire stent. In some cases, expandable member 110 includes a shape memory material (e.g., a nickel-titanium alloy or a cobalt-chromium alloy).


Referring to FIGS. 2A-2C, a leaflet 200 can include a body portion 214 and sleeve portions 216. In some cases, the body portion 214 has a bottom edge 222, a first side edge 226, a second side edge 228, and a free edge 224. Leaflet 200 further includes a front (i.e., the side that blood flows toward), a back (i.e., the side that blood flows away from), a first side adjacent to the first side edge 226, and a second side adjacent to the second side edge 228. In some cases, the front of the leaflet 200 has a different texture than the back. In some cases, for example, the back of the leaflet may be prone to calcium build due to its cusp-shaped surface, therefore it can be beneficial to have a textured surface on the back of the leaflet to mitigate valve calcification issues. In some cases, however, having the back with a non-textured surface can mitigate calcification issues. In some cases, the leaflet 200 is made from tissue obtained from an animal, e.g., a pig or a cow. In some cases, leaflet 200 is made from bovine pericardium. Leaflets 200 can also be made from a synthetic material. Leaflets 200 can be assembled into a heart valve by aligning the opposite side regions of at least two adjacent leaflets 200 and stitching the leaflets 200 together along stitch line 246, as shown in FIG. 2C.


As shown in FIGS. 2A-2C, a prosthetic heart valve can include at least one leaflet 200 having a body portion 214 and two opposite sleeve portions 216. The body portion 214 can be defined by two side edges 226, 228 adjacent each sleeve portion 216. The at least one leaflet 200 can define at least one notch 232, 234 between at least one of the two side edges 226, 228 and the adjacent sleeve portion 216. In other words, each notch 232, 234 can be located along the side edges 228, 226 at a location that is adjacent to the sleeve portions 216, at an armpit of the leaflet 200, as depicted in FIGS. 2A and 2B. In some cases, leaflet 200 can define a notch 232, 234 generally along the side edges 228, 226. In some cases, a notch 232, 234 can be defined along the sleeve portion 216. In some cases, multiple notches 232, 234 can be located along the sleeve portion 216 or one of the side edges 228, 226, and/or at the armpit of the leaflet 200.


As shown in FIG. 2A and 2B, the body portion 214 of the leaflet can have a conical frustum shape defined by a bottom edge 222, the first side edge 226, the second side edge 228, and a free edge 224. In some cases, other suitable shapes for the body portion can be contemplated, for example, a generally square, rectangular, triangular or trapezoidal shaped body portion.


The sleeve portions, as shown in FIGS. 2A-2C, can extend outwardly from the body portion of the leaflet 200. Each sleeve portion may be angled away from free edge of the body portion. Sleeve portions can be generally rectangular-shaped extensions with lateral ends. In some cases, the sleeve portions can have rounded ends.


Still referring to FIGS. 2A-2C, notches 232, 234 can be generally U-shaped. Other suitable notch shapes can include, but are not limited to, a V-shaped, Z-shaped, rectangular-shaped and an oval-shaped notch. Notches can also have rounded edges to smooth the transition between a notch and the side edges 228, 226 of the leaflet 200. Notches 232, 234 can have a length dimension that can range from about 0.02 inches to about 0.20 inches (or from about 0.5 millimeters (mm) to about 4 mm).


Referring to FIG. 2C, notches 232, 234 can be shaped and sized to accommodate attachment of post leg compression elements 122. Post leg compression elements 122 can be a part of anchor elements 120 (shown in FIGS. 1A and 1B) that compress and restrain sleeve portions 216 along the same line as the stitch line 246. A suture 258 can be used to apply an appropriate and consistent compressive force between the post leg compression elements 122 in order to prevent leakage through sleeve portions 216 of the leaflets 200. Sutures that pierce the body portion 214 at or near the armpit of the leaflet, however, can pull, stretch and abrade the surrounding adjacent tissue, creating stress concentrations at or near the armpit of the leaflet. Stress concentrators can result in tears forming in the leaflet material. Using notches 232 and 234 and post leg compression elements 122, however, can minimize potential heart valve tearing caused by sutures at or near the armpit location. Notches 232, 234 can be positioned proximate to the post leg compression elements near the armpit of the leaflet, e.g., between at least one of the two side edges 226, 228 and the adjacent sleeve portion 216, to create enlarged openings that suture 258 can pass therethrough without pulling or stretching the adjacent tissue. Accordingly, a notched leaflet 200 can improve valve opening capabilities and the reliability of prosthetic heart valves provided herein.



FIG. 3 illustrates another exemplary leaflet, which can be used in prosthetic heart valves provided herein. As shown in FIG. 3, leaflet 300 can include a body portion 314 and at least two opposite sleeve portions 316. The body portion 314 can be defined by at least two side edges 326, 328 adjacent each sleeve portion 316. Leaflet 300 can define two apertures 332 and 334. Each aperture 332, 334 can be positioned adjacent the side edges 326, 328 and an adjacent sleeve portion 316. Each aperture 332, 334 can be adapted to secure one leaflet to an adjacent leaflet.


In some cases, the body portion 314 has a bottom edge 322, a first side edge 326, a second side edge 328, and a free edge 324. Leaflet 300 further includes a front, a back, a first side adjacent to the first side edge 326, and a second side adjacent to the second side edge 328. In some cases, the front of the leaflet 300 has a different texture than the back. In some cases, this occurs where the leaflet 300 is made from pig, cow, or other natural animal tissue. In some cases, leaflet 300 is made from bovine pericardium. Leaflets 300 can also be made from a synthetic material. Leaflets 300 can be assembled into a heart valve by aligning the opposite side regions of at least two adjacent leaflets 300 and stitching the leaflets 300 together along stitch line 246, as shown in FIG. 2C.


As shown in FIG. 3, leaflet 300 defines apertures 332 and 334 adjacent the side edges 328, 326 and adjacent the sleeve portions 316. Apertures 332 and 334 can be generally circular in shape. Other suitable aperture shapes can include, for example, a rectangular, an oval, a triangular, or a diamond shape. In some cases, apertures 332, 334 can have a length dimension or a diameter from about 0.02 inches to about 0.20 inches (or from about 0.5 mm to about 4 mm). In some cases, one or more apertures 332, 334 can be located in the side edges 328, 326 and/or the sleeve portions 316 of the leaflet 300. In some cases, multiple apertures can be located in a region that is adjacent to the side edges 328, 326 and the sleeve portions 316.


Apertures 332, 334 in the leaflets 300 can allow one leaflet to be secured to an adjacent leaflet. Similar to the notches discussed above, apertures 332 and 334 can be shaped and sized to accommodate attachment of post leg compression elements 122. Referring back to FIGS. 1A and 1B post leg compression elements 122 can be a part of anchor elements 120 that compress and restrain sleeve portions 216 along the same line as the stitch line 246. A suture 258 can be used to apply an appropriate and consistent compressive force between the post leg compression elements 122 in order to prevent leakage through sleeve portions 216 of the leaflets 200. As already discussed herein, sutures that pierce the body portion 214 at or near the armpit of the leaflet can create stress concentrations at or near the armpit of the leaflet that may result in tearing. Apertures 332 and 334 and post leg compression elements 122, however, can minimize this potential tearing caused by sutures near the armpit location. Apertures 332, 334 can be positioned proximate to the post leg compression elements near the armpit location to create enlarged openings that suture 258 can pass therethrough without pulling or stretching the adjacent tissue. Accordingly, leaflets 300 used in prosthetic heart valves provided herein can improve the reliability of prosthetic heart valves provided herein.



FIGS. 4A-4G depict how leaflets 200 can be connected (or jointed) with an improved stitch discussed herein. As shown, stitch 446 can be a single continuous line stitch traveling along a stitch line in a forward direction and back in a reverse direction. In some cases, stitch 446 can run along a leaflet from a bottom edge to a side edge of the leaflet (e.g., bottom edge 222 to side edge 226 of leaflet 200 in FIG. 2A-2B). In some cases, stitch 446 can run from a side edge to a notch of a leaflet (e.g., side edge 226 to notch 234 of leaflet 200 in FIG. 2A-2B).


As shown in FIGS. 4D-4G; stitch 446 can include a plurality of perpendicular loop segments 434 extending through an aperture in the two leaflets, around outer side edges of the two attached leaflets, and back through the aperture. Stitch 446 can include a plurality of parallel segments 436 extending between adjacent apertures along the stitch line. Stitch 446 can include two perpendicular loop segments 434 extending through apertures formed in the stitch line. In some cases, a first perpendicular loop segment 434 for a first aperture in the stitch line is formed when the stitch is formed in the forward direction and a second perpendicular loop segment 434 for the first aperture is formed in the reverse direction. In some cases, parallel segments 436 made in a forward direction alternate between opposite sides of the two leaflets between each aperture in the stitch line. In some cases, parallel segments 436 made in a reverse direction are formed on an opposite side of the two leaflets from parallel segments 436 made in a forward direction. In some cases, opposite parallel segments 436 made in the forward and reverse directions can provide a continuous compressive force along the entire length of the stitch line. Perpendicular loop segments 434 can provide compressive force to reinforce a seal formed between the two leaflets along the stitch line.


Stitch 446 can include any appropriate number of perpendicular loop segments formed through any appropriate number of apertures. As shown, stitch 446 includes six perpendicular loop segments formed through six apertures (two perpendicular loop segments per aperture). In some cases, stitch 446 can include up to twelve perpendicular loop segments formed through six or more apertures. In some cases, a stitch connecting side edge segments of leaflets can be formed using between 3 and 20 apertures and include between 3 and 40 perpendicular loop segments. In some cases, apertures can be positioned from about 0.008 inches to about 0.4 inches apart (about 0.2 mm to about 10 mm apart). In some cases, apertures can be positioned from about 0.008 inches to about 0.4 inches (about 0.2 mm to about 10 mm) away from the side edges of the leaflets.


Stitch 446 can be formed in a process depicted in FIGS. 4A-4G As shown in FIG. 4A, a thread needle 410 can be passed through aligned leaflet side edges 226a and 226b to create a first aperture at a location near bottom edges 222, e.g., a location approximately 1 mm from the bottom edges 222. The leaflet side edges 226a and 226b can be retained in a desired configuration by clamping the leaflets between clamp sides 422 and 424. Needle 410 pulls a leading end 431 of a thread 432 through the first aperture. As shown in FIG. 4B, needle 410 can then form a second aperture adjacent to the first aperture along the stitch line (towards the leaflet sleeve portion) about 0.5 mm away from the first aperture to pull leading end 431 of thread 432 through the second aperture to form a first parallel segment. As shown in FIG. 4C, a perpendicular loop segment 434 can be made by guiding needle 410 around the leaflet side edges and re-enter the second aperture from a backside. Thread 432 can be pulled through the second aperture until it sits firmly against the leaflet material (e.g., leaflet pericardium tissue). FIG. 4D shows a second parallel segment, which can be made by pushing needle 410 through leaflet tissue along the stitch line to form a third aperture approximately 1 mm from the second aperture (towards the sleeve segments of the leaflet). As shown in FIG. 4E, a second perpendicular loop segment 434 can be formed by again having needle 410 loop around the leaflet side edges and reenter the third aperture through the backside. This is repeated up to notch 234 to form a total of six parallel segments 436 and six perpendicular loop segments 434 in a forward direction, as shown in FIG. 4F. The stitch pattern can then be repeated in a reverse direction towards the bottom edges 222 of the leaflets through the previously formed apertures. Accordingly, each aperture can include two perpendicular loop segments 434 and parallel segments on the opposite sides can be formed from the parallel segments that were created in the forward direction, as shown in FIG. 4G The method and stitches depicted in FIGS. 4A-4G can be applicable to leaflets 200, 300 discussed herein.


Stitch 446 and other stitches provided herein can improve the reliability of a seal formed along a stitch line, create fewer apertures through the leaflets, and simplify the stitching operation. Having fewer apertures can help minimize the occurrence of blood leakage through the apertures. The single continuous line of stitch 446 using a single row of apertures can minimize a width of a side edge portion needed to form a continuous seal along the side edges of the leaflets, thus providing a reduced restricted profile for prosthetic heart valves provided herein. For example, U.S. Pat. No. 8,778,020 describes a variety of ways that leaflets can be sutured together using combinations of whip stitches and running stitches, but these stitches require additional apertures and multiple lines. Perpendicular loop segments 434 can stitch a plurality of leaflets together, similar to the whip stitches discussed in U.S. Pat. No. 8,778,020. Parallel segments 436 can secure valve leaflets to one another, similar to the running stitches discussed in U.S. Pat. No. 8,778,020. Although stitch 446 can provide an improved attachment between side edges of leaflets in prosthetic heart valves provided herein, some embodiments of prosthetic heart valves provided herein can use other stitch patterns, such as those described in U.S. Pat. No. 8,778,020, which is hereby incorporated by reference.


Important characteristics of the thread can include, but are not limited to, tensile strength, abrasion resistance and creep rupture resistance characteristics that allow the device to be delivered and implanted into a human anatomy. The thread used for suturing together portions of the heart valve, e.g., sides edges of the leaflets, can be composed of biocompatible materials that include, but are not limited to, polyethylenes such as ultra high molecular weight polyethylene (UHMWPE), polyesters (PET), and combinations thereof.


Referring back to FIGS. 1A and 1B, prosthetic heart valve 100 can include a tubular seal 130. Tubular seal 130 can be secured to bottom edges 222 (FIG. 2A) of the body portion 214 of at least one leaflet 200 by a circumferential running stitch 134 within prosthetic heart valve 100. Tubular seal 130 can be secured to expandable tubular member 110 by fasteners 136 and extended around the outside of expandable tubular member 110 to provide a seal that minimizes blood leakage around the leaflets 200 of an implanted prosthetic heart valve 100. The structure and materials of tubular seal 130 are discussed below in reference to FIGS. 6 and 7A-7E.


Referring to FIGS. 5A-5C, an improved tubular seal stitching pattern can include a cross stitch 132 between tubular seal 130 and expandable member 110. FIGS. 5A-5C illustrate how the tubular seal 130 can be secured to the expandable member 110, e.g., a braided stent, by a plurality of cross stitches connecting the tubular seal 130 to a pair of overlapping wire members of the braided stent. As shown in FIGS. 1A, 1B and 5A-5C, expandable member 110 can be a braided stent including one or more wires having a first set of segments 114 extending helically in a first direction and a second set of segments 116 extending helically in a second direction such that the first set of segments 114 cross the second set of segments 116 at intersection points 118. As shown, one or more wires can have inflow crowns 115 at an end of the braided stent where the wires transition from first segments 114 to second segments 116. In some cases, cross stitches 132 secure tubular seal 130 at an intersection 118 to two crossing segments 114, 116 of the braided stent. A separate circumferential running stitch 134 can be inserted into preformed apertures 133 to secure the adaptive seal to bottom edges 222 of leaflets 200 shown in FIGS. 2A and 2C. Cross-stitches around the intersections 118 can increase the strength of an attachment of tubular seal 130 to the expandable member 110 while also allowing for improved load transfer to the expandable member 110. In some cases, the cross stitches secure tubular seal 130 at intersections 118 located immediately above (proximal) the inflow crowns 115. Cross stitches 132 can be formed by passing two stitches 132a, 132b of a suture in orthogonal directions over the intersections 118 and through the tubular seal 130. In some cases, preformed apertures 131 for cross stitch 132 can be formed in the tubular seal 130. In some cases, a portion of the tubular seal 130 that is sutured by cross stitch 132 includes an internal fabric, such as those discussed below. Each cross stitch 132 can be knotted independently. As shown in FIG. 5C, cross stitches 132 each include a separate knot 137. Additionally, cross stitches 132 can be arranged to not pass through leaflets 200. Cross stitches 132 can be repeated at a plurality of intersections 118 (FIG. 5A) circumferentially around an inflow end of a prosthetic heart valve provided herein such that an entire circumference of tubular seal 130 is securely attached. In some cases, each intersection 118 immediately adjacent to inflow crowns 115 is sutured to tubular seal 130 via a cross stitch provided herein. The tubular seal stitching pattern provided herein can increase the strength of the attachment between the tubular seal 130 and the expandable member 110 while also allowing for improved load transfer to the expandable member 110 through the use of the plurality of cross stitches.


Tubular seal 130 can have any suitable structure. In some cases, tubular seal 130 can include an elastic material. In some cases, tubular seal 130 can include one or more layers of an elastomeric polymer. In some cases, tubular seal 130 can include a polycarbonate, polyurethane, silicone, polytetrafluoroethylene (PTFE), or a combination thereof. Other suitable materials include, but are not limited to, natural and synthetic rubbers, including cis-1,4-polyisoprene rubber, styrene/butadierie copolymers, polybutadiene rubber, styrene/isoprene/butadiene rubber, butyl rubber, halobutyl rubber; polyurethane elastomers, including elastomers based on both aromatic and aliphatic isocyanates; flexible polyolefins, including flexible polyethylene and polypropylene homopolymers and copolymers; styrenic thermoplastic elastomers; polyamide elastomers; polyamide-ether elastomers; ester-ether or ester-ester elastomers; flexible ionomers; thermoplastic vulcanizates; flexible poly(vinyl chloride) homopolymers and copolymers; flexible acrylic polymers; and blends and alloys of these, such as poly(vinyl chloride) alloys like poly(vinyl chloride)-polyurethane alloys. In some cases, tubular seal 130 can include an aliphatic polycarbonate-based thermoplastic urethane. In some cases, tubular seal 130 can include an elastomeric polymer having a hardness ranging from 3.07 MPa to 9.9 MPa, or a durometer ranging from 75 Shore A to 75 Shore D using ASTM standard D2240 in force on Jan. 1, 2014. In some cases, tubular seal 130 can include a polymeric material having the mechanical properties shown in Table I below. Notably, all of the listed ASTM standards refers to the standard in force on Jan. 1, 2014.











TABLE I









ASTM Standard





Durometer Range
75 Shore A-75 Shore D
D2240


Available


Specific Gravity
1.10-1.14
D792


Melt Flow
2-26 g/10 min (205° C./3.26 kg)
D1238













MECHANICAL
ASTM



PROPERTY RANGES
Standard











Durometer
75A-B20
55D
75D
75D





Ultimate Tensile
 400-9000
 5000-10000
3000-8000
D638


Strength (psi)


Tensile (psi)


@50% elongation
350-650
1500-1800
3000-8000
D638


@100% elongation
550-850
1800-2200
3000-8000
D638


@200% elongation
 600-1200
2800-4200

D638


@300% elongation
1200-2000
 4200-10000

D630


Ultimate Elongation
350-750
200-400
100-300
D638


(%)









In some cases, referring back to FIG. 1A, tubular seal 130 can include attachment structures to improve the attachment of the tubular seal 130 to leaflets 200 and/or expandable member 110.


In some cases, as shown in FIG. 7A, a tubular seal 730 can include an inflow end section 740 and an outflow end section 750. The inflow end section 740 can include a fabric embedded within elastomeric material and the outflow end section 750 can include a plurality of grommets 732. The fabric of inflow end section 740 can be a woven material. In some cases, the fabric can have warp threads and/or weft threads. The fabric is composed of fibers having an average thread diameter from about 0.00002 inches to about 0.002 inches (or from about 0.5 microns to about 50 microns), more preferably from about 0.0008 inches to about 0.002 inches (or from about 20 micron to about 40 microns). In some cases, more preferably, the fabric is composed of fibers having a thread diameter of about 0.0011 inches (about 27 microns).


In some cases, the fabric can include non-elastomeric fibers. Suitable non-elastomeric fiber materials include, but are not limited to, polyolefins, polyesters such as PES 38/31 manufactured by SaatiTech, and polyamides. More particularly, the polyolefins may be, for example, one or more of polyethylene, polypropylene, polybutene, ethylene copolymers, propylene copolymers, and butene copolymers. Because the fabric can include non-elastic fibers, inflow end section 740 and outflow end section 750 can have different overall elastic properties. In some cases, tubular seal 730 can be used as a tubular seal 130 of prosthetic heart valve 100, as previously shown in FIG. 1A. In some cases, tubular seal 730 can be used in other prosthetic heart valves provided herein.


As shown in FIGS. 7A-7D, an interface 753 between the inflow end section 740 and the outflow end section 750 is non-linear due to a non-linear edge of fabric within the inflow end section 740. As shown in FIG. 7A, the non-linear edge can be sinusoidal 753. In some cases, as shown in FIGS. 7C-7D, the non-linear edge can be a zigzagged edge 754, a stepped edge 755, or a scalloped edge 756.


In some cases, inflow end section 740 can be thicker than outflow end section because of the presence of a fabric within inflow end section 740, 750. In some cases, inflow end section 740 can have a thickness of about 0.0028 inches (about 70 microns) and the outflow end section 750 can have a thickness of about 0.0020 inches (about 50 microns). Other suitable thicknesses for the inflow end section include thicknesses ranging from about 0.0020 inches to about 0.0035 inches (about 50 microns to about 90 microns), or more preferably, from about 0.0025 inches to about 0.0031 inches (about 60 microns to about 80 microns). Suitable thicknesses for the outflow end section include thicknesses ranging from about 0.0011 inches to about 0.0028 inches (about 30 microns to about 70 microns), or more preferably, from about 0.0016 inches to about 0.0023 inches (about 40 microns to about 60 microns). In some cases, suitable thickness ratios of the inflow end section relative to the outflow end section can range from 1:1 to 1.2:1, from 1.2:1 to 1.4:1, from 1.4:1 to 1.5:1, and from 1.5:1 to 2:1. A non-linear edge can providing a non-linear interface between the inflow end section 740 and the outflow end section 750. A prosthetic heart valve with the non-linear interface may have an increased overall diameter that tapers more gradually when compared to a prosthetic heart valve that has a linear interface. The non-linear edge of the fabric can also gradually transition the change in elastic properties between the outflow end section 750 and the inflow end section 740, mitigating the formation of stress concentrators along the interface 753 that can cause tearing in the tubular member. Additionally, the shape of non-linear interface 753 can limit the propagation of tears.


In some cases, the fabric can be arranged in the inflow end section 740 to allow for the fabric within inflow end section 740 to stretch in axial and/or radial directions to allow the tubular seal to stretch along with an expandable member during implantation. When the fabric does not allow the tubular seal to adequately stretch, the seal can cause non-uniform crimping during manufacturing or damage the expandable member during device deployment. In some cases, a woven fabric can be arranged to have the warp and the waft extend in directions oblique to the axis of the tubular seal. This can allow the fabric to flex in radial and/or axial directions relative to the axis of the tubular seal, but limit the fabric from stretching in a direction oblique to the axis. In some cases, both the warp and the waft can extend at an angle between 30 degrees and 60 degrees with the axis of the tubular seal. In some cases, both the warp and the waft can extend at an angle between 5 degrees and 70 degrees with the axis of the tubular seal. In some cases, the warp and waft can be arranged within the tubular member 730 to form an angle of about 45 degrees with the axis of the tubular seal. In some cases, the fabric can be a knit fabric arranged to allow for a predetermined amount of stretch in the axial and/or radial directions. Limiting the fabric within inflow end section 740 from stretching in a direction oblique to the axis can prevent the fabric from bunching and minimize non-uniform crimping during manufacturing.


Additional exemplary tubular seals including a fabric and grommets are described in U.S. Patent Application No. 2013/0090729, which is hereby incorporated by reference in its entirety. For example, U.S. Pat. No. 8,778,020 describes a seal that includes a multilayer, cylindrical seal body having projections alternating with recesses along the proximal edge of the seal body with proximal reinforcing grommets and a distal reinforcing band, which may be formed from a woven or nonwoven fabric and either incorporated within the interior of the multilayer seal body or adhered to the surface thereof.


In some cases, tubular seals described in U.S. Patent Application No. 2013/0090729 can be modified to include a fabric arrangement that allows a seal to stretch in axial and/or radial directions. In some cases, elastomeric materials provided herein can be incorporated into the tubular seals disclosed in U.S. Patent Application No. 2013/0090729. In some cases, the tubular seals described in U.S. Patent Application No. 2013/0090729 can be modified to include the non-linear interface 753 provided herein.


Referring back to FIG. 7A, tubular seal 730 can be created by producing one or more layers of elastomeric polymer, applying the fabric and grommets 732 to the one or more layers of elastomeric polymer, and overcoating the fabric and grommets 732 with one or more additional layers of elastomeric material. In some cases, different layers can have different elastomeric properties. In some cases, tubular seals (e.g., 130, 730, or 760) can include a radially innermost layer including at least one elastomeric polymer, e.g., a polycarbonate and a polyurethane; a radially outermost layer including at least one elastomeric polymer, e.g., a polycarbonate and a polyurethane; and at least one inner layer disposed between the radially outermost layer and a radially innermost layer. In some cases, the modulus of elasticity of the innermost layer is less than the modulus of elasticity of the radially innermost outer layer and the modulus of elasticity of the radially outermost outer layer. In some cases, the elongation to break of the inner layer is greater than the elongation to break of the radially innermost outer layer and the elongation to break of the radially outermost outer layer. Although the radially innermost outer layer and the radially outermost outer layer have been depicted as including the same material, it will be appreciated that they may be compositionally the same or different.


The multilayer tubular seals provided herein (e.g., 130, 730, 760) may be formed in a variety of ways. In some cases, multilayer tubular seals provided herein may be formed by successive applications of a polymer solution to an appropriately shaped mandrel, such as that illustrated in FIG. 6. Following a careful cleaning of the mandrel 600, the mandrel may be mounted to an appropriate holding fixture in a spray booth. A first coating composition including a carrier and at least one polymer may be applied to the mandrel 600 and subsequently dried to form a first coated mandrel. In some cases, the first coating composition includes one or more elastomeric polymers, e.g., polycarbonate and/or a polyurethane, and a volatile carrier. The coating composition may be applied as a single layer or multiple layers to achieve the desired dried coating thickness. The grommets 732 (FIG. 7A) and the fabric may be positioned on the first coated mandrel by inserting locating pins 620 in apertures 610 in the tapered mandrel 600 which align with corresponding perforations 30 provided in the grommets 32, 34, 36 and the fabric 40. In FIG. 6, only one pin 620 has been illustrated for clarity. In some instances, it may be desirable to secure the plurality of grommets 732 and the fabric to the mandrel or to an underlying coating layer by applying a drop of a first coating composition, or other adhesive composition, to each item to ensure that it remains properly positioned during subsequent processing. The fabric can be cut to a suitable shape having a non-linear edge using any suitable method. In some cases, the fabric can be die cut. In some cases, the fabric can be cut with a blade. In some cases, the fabric can be cut using a femtosecond laser. In some cases, a femtosecond laser cut fabric mitigate the chances of forming stress concentrators along the edge of the fabric.


A second coating composition including a carrier and at least one polymer may be applied to the first coated mandrel, the fabric, and the plurality of grommets. In some cases, the second coating composition includes one or more elastomeric polymers, e.g., polycarbonate and/or a polyurethane, and a volatile carrier. The carrier of the second coating composition may be removed, thereby forming a second coated mandrel. The second coating composition may be applied as a single layer or as multiple layers to achieve the desired dried coating thickness. In some cases, the second coating composition may be different from the first coating composition. In some cases, the second coating composition may be composed of the same material as the first coating composition.


In some cases, a third coating composition including a carrier and at least one polymer may be applied to the second coated mandrel. In some cases, the third coating composition includes one or more elastomeric polymers, e.g., polycarbonate and/or a polyurethane, and a volatile carrier. The carrier of the third coating composition may be removed thereby forming a tubular seal precursor. The third coating composition may be applied as a single layer or as multiple layers to achieve the desired dried coating thickness. In some cases, the third coating composition may be different from the first coating composition. In some cases, the third coating composition may be the same as the first coating composition. In some cases, the third coating composition may be different from the second coating composition. In some cases, the third coating composition may be the same as the second coating composition. Following removal of the carrier from the third coating composition, the tubular seal precursor may be inspected to ensure that it is fully formed and meets dimensional specifications, such as a thickness specification. In some cases, a suitable thickness for the tubular seal precursor can range from about 0.001 inches to about 0.0030 inches (about 30 microns to about 75 microns) or from about 0.002 inches to about 0.0047 inches (about 50 microns to about 120 microns). Other suitable thicknesses for the tubular seal precursor include a range from about 0.0008 inches to about 0.002 inches (about 20 microns to about 40 microns), about 0.001 inches to about 0.002 inches (about 30 microns to about 50 microns), about 0.002 inches to about 0.0029 inches (about 50 microns to about 75 microns), about 0.002 inches to about 0.004 inches (about 50 microns to about 100 microns), about 0.004 inches to about 0.0047 inches (about 100 microns to about 120 microns), about 0.004 inches to about 0.0059 inches (about 100 microns to about 150 microns), about 0.0059 inches to about 0.0079 inches (about 150 microns to about 200 microns), as well as any thickness value within any of the listed ranges.


In some cases, the tubular seal precursor may be inspected to ensure that it meets certain functional specifications, e.g., tensile and frictional specifications. The tubular seal precursor may then be trimmed by laser cutting, or blade cutting, to conform to dimensional specifications and removed from the tapered seal-forming mandrel as a formed tubular seal. In some cases, at least some preformed apertures for suturing tubular seal to expandable member 110 and/or leaflets 200 can be performed by laser cutting. In some cases, at least some of the grommets may be formed by a laser cutting operation performed on a tubular seal precursor. In some cases, grommets 732 of FIG. 7A may be added to the multilayer, generally cylindrical seal, in a step not illustrated, as a proximal band. Subsequent laser cutting of the tubular seal precursor would then simultaneously form grommets 732 by removing the portions of the proximal band located between the projections.


In some cases, coating compositions may be selected to provide a relatively stiff dried polymer such as a dried polymer having a Shore D hardness of about 55, or a hardness of about 6.21 Megapascals (Mpa). In some cases, coating compositions may be selected to provide a relatively elastomeric dried polymer such as a dried polymer having a Shore A hardness of about 80, or a hardness of about 3.45 MPa. In some cases, the first and third dried polymer layers may have a Shore D hardness of 55, or a hardness of 6.21 MPa, and the second layer may have a Shore A hardness of 80, or a hardness of 3.45 MPa.


Although in some cases described above, three polymer layers were employed, it will be appreciated that a greater or lesser number of layers may be employed and that each of the three or more layers may include two or more sublayers. In some cases, the plurality of grommets and the fabric can be positioned between the first and second coating layers. In some cases, the plurality of grommets and the fabric can be positioned elsewhere within the tubular seal, e.g., within a layer, or on the radially innermost or radially outermost surface of the tubular seal.


The mandrel 600 of FIG. 6 includes a taper which results in a tubular seal having a slightly smaller diameter proximal end compared to the diameter of the distal end. In some cases, the diameter of the proximal end can include a diameter reduction of about 3% to about 30% as compared to the diameter of the distal end. The taper allows the tubular seal to be removed from the mandrel with relative ease upon completion of the fabrication process. The smaller proximal diameter of the tubular seal tends to cause the proximal projections to lie more firmly against an anchor element of the replacement heart valve. In some cases, the surface of the mandrel may be textured to create a tubular seal with a reduced contact area. In some cases, the mandrel can be textured using a bead blasting process. In combination with the selection of a relatively hard outer layer, a textured seal surface is believed to result in a lower friction surface.


As shown in FIG. 7E, a tubular seal 760 can include a woven or non-woven fabric embedded throughout a polymer or metal matrix structure. In some cases, at least one leaflet of the heart valve can be secured to the tubular seal in a portion of the tubular seal including the woven or non-woven fabric to minimize blood leakage between the tubular seal and the leaflets.


In some cases, the matrix structure can be made of elastomeric material. In some cases, tubular seal 760 can be made of the fabric alone. The fabric can include non-elastic fibers arranged to allow for the tubular seal 760 to stretch in axial and/or radial directions relative to the axis of the tubular seal 760. In some cases, the non-elastic fibers can be arranged within the tubular member 760 to form an angle of about 45 degrees with the axis of the tubular seal. In some cases, the fabric can be a knit fabric arranged to allow for a predetermined amount of stretch in the axial and/or radial directions. In some cases, the fabric can be made of polymeric materials that include, but are not limited to, polyesters, polyolefins such as polyethylene and polypropylene, polyamides, nylons, and combinations thereof. In some cases, the fabric can have a thickness ranging from about 0.002 inches to about 0.003 inches (about 40 to about 80 microns). In some cases, the fabric can be woven such that spacings between individual fibers create openings in the fabric that together constitutes from about 20% to about 40% of a fabric surface.


A tubular seal having a fabric embedded throughout the elastomeric material can simplify the manufacturing process. For example, instead of requiring the use of the mandrel 600 to build up layers of elastomeric polymer and position a fabric in select portions of the tubular seal, tubular seal 760 can be created by coating a continuous tube of fabric including non-elastic fibers with an elastomeric polymer and cutting the tube into individual tubular seals. In some cases, a tube of fabric can be stretched in an axial direction during the coating of the fabric with the elastomeric polymer to enable the tubular seal to have more stretch in a radial direction than an axial direction.


A number of embodiments of the invention have been described. Nevertheless, it will be understood that various modifications may be made without departing from the spirit and scope of the invention. Accordingly, other embodiments are within the scope of the following claims.

Claims
  • 1. A prosthetic heart valve comprising: an expandable tubular member;a plurality of leaflets secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member and a free edge at a blood outflow end of the expandable tubular member; anda tubular seal secured to the bottom edge of each leaflet and along an outer portion of the expandable tubular member, wherein the tubular seal comprises an elastomeric polymer matrix and a plurality of non-elastic fibers retained within the matrix, and wherein the non-elastic fibers are arranged in the elastomeric polymer matrix to allow the tubular seal to stretch in axial and radial directions.
  • 2. The prosthetic heart valve of claim 1, wherein the non-elastic fibers are part of a fabric.
  • 3. The prosthetic heart valve of claim 2, wherein the fabric is a woven fabric.
  • 4. The prosthetic heart valve of claim 3, wherein the woven fabric comprises fibers in a warp direction and fibers in a waft direction, wherein the fibers in both the warp direction and the waft direction are angled with respect to a central axis of the tubular seal.
  • 5. The prosthetic heart valve of claim 3, wherein the fibers in both the warp direction and the waft direct are angled at an angle of between 5 degrees and 70 degrees with respect to the central axis of the tubular seal.
  • 6. The prosthetic heart valve of claim 1, wherein the non-elastic fibers are uniformly dispersed throughout the elastomeric polymer matrix.
  • 7. The prosthetic heart valve of claim 6, wherein the tubular seal has a substantially uniform thickness.
  • 8. The prosthetic heart valve of claim 6, wherein the tubular seal comprises an outflow end region and an inflow end region, the inflow end region being a portion of the tubular seal comprising the fabric, wherein the fabric has a non-linear edge defining the interface between the inflow end region and the outflow end region.
  • 9. The prosthetic heart valve of claim 8, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.
  • 10. The prosthetic heart valve of claim 8, wherein the inflow end region comprises a first substantially uniform thickness and the outflow end region comprises median thickness that is less than the first substantially uniform thickness.
  • 11. The prosthetic heart valve of claim 8, wherein the outflow end region comprises a plurality of grommets.
  • 12. The prosthetic heart valve of claim 1, wherein the tubular seal has a thickness range from about 30 microns to about 75 microns.
  • 13. The prosthetic heart valve of claim 1, wherein the tubular seal has a thickness range from about 50 microns to about 120 microns.
  • 14. A prosthetic heart valve comprising: an expandable tubular member;a plurality of leaflets secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member and a free edge at a blood outflow end of the expandable tubular member; anda tubular seal comprising an elastomeric polymer matrix and a fabric comprising a plurality of non-elastic fibers retained within an inflow end portion of the elastomeric polymer matrix, the inflow end portion of the tubular seal being secured to the bottom edges of the plurality of leaflets, wherein the fabric comprises a non-linear edge within the elastomeric polymer matrix.
  • 15. The prosthetic heart valve of claim 14, wherein the non-linear edge of the fabric has a sinusoidal or scalloped shape.
  • 16. The prosthetic heart valve of claim 14, wherein the non-elastic fibers comprise a polyester.
  • 17. The prosthetic heart valve of claim 14, wherein the elastomeric polymer matrix comprises a first material composition and a second material composition, wherein the first material composition is different than the second material composition.
  • 18. The prosthetic heart valve of claim 14, wherein the elastomeric polymer matrix comprises a polymer selected from polycarbonates, polyurethanes, silicones, and combinations thereof.
  • 19. The prosthetic heart valve of claim 14, wherein the elastomeric polymer matrix comprises a polymer having a hardness ranging from 75 Shore A to 75 Shore D.
  • 20. A prosthetic heart valve comprising: an expandable tubular member;a plurality of leaflets secured together along side edges and retained within the expandable tubular member, each leaflet having a bottom edge at a blood inflow end of the expandable tubular member; anda tubular seal comprising a polymer matrix and a fabric retained within an inflow end portion of the polymer matrix, wherein the fabric comprises a non-linear edge within the polymer matrix.
RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/111,449, filed Feb. 3, 2015.

US Referenced Citations (922)
Number Name Date Kind
15192 Peale Jun 1856 A
2682057 Lord Jun 1954 A
2701559 Cooper Feb 1955 A
2832078 Williams Apr 1958 A
3029819 Starks Apr 1962 A
3099016 Edwards Jul 1963 A
3113586 Edmark, Jr. Dec 1963 A
3130418 Head et al. Apr 1964 A
3143742 Cromie Aug 1964 A
3221006 Moore et al. Nov 1965 A
3334629 Cohn Aug 1967 A
3365728 Edwards et al. Jan 1968 A
3367364 Cruz, Jr. et al. Feb 1968 A
3409013 Berry Nov 1968 A
3445916 Schulte May 1969 A
3540431 Mobin-Uddin Nov 1970 A
3548417 Kischer et al. Dec 1970 A
3570014 Hancock Mar 1971 A
3587115 Shiley Jun 1971 A
3592184 Watkins et al. Jul 1971 A
3628535 Ostrowsky et al. Dec 1971 A
3642004 Osthagen et al. Feb 1972 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3725961 Magovern et al. Apr 1973 A
3755823 Hancock Sep 1973 A
3795246 Sturgeon Mar 1974 A
3839741 Haller Oct 1974 A
3868956 Alfidi et al. Mar 1975 A
3874388 King et al. Apr 1975 A
3983581 Angell et al. Oct 1976 A
3997923 Possis Dec 1976 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4084268 Ionescu et al. Apr 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4233690 Akins Nov 1980 A
4265694 Boretos et al. May 1981 A
4291420 Reul Sep 1981 A
4297749 Davis et al. Nov 1981 A
4323358 Lentz et al. Apr 1982 A
4326306 Poler Apr 1982 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4388735 Ionescu Jun 1983 A
4406022 Roy Sep 1983 A
4423809 Mazzocco Jan 1984 A
4425908 Simon Jan 1984 A
4470157 Love Sep 1984 A
4484579 Meno et al. Nov 1984 A
4501030 Lane Feb 1985 A
4531943 Van Tassel et al. Jul 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4580568 Gianturco Apr 1986 A
4592340 Boyles Jun 1986 A
4602911 Ahmadi et al. Jul 1986 A
4605407 Black et al. Aug 1986 A
4610688 Silvestrini et al. Sep 1986 A
4612011 Kautzky Sep 1986 A
4617932 Kornberg Oct 1986 A
4643732 Pietsch et al. Feb 1987 A
4647283 Carpentier et al. Mar 1987 A
4648881 Carpentier et al. Mar 1987 A
4655218 Kulik et al. Apr 1987 A
4655771 Wallsten Apr 1987 A
4662885 Dipisa, Jr. May 1987 A
4665906 Jervis May 1987 A
4680031 Alonso Jul 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4705516 Barone et al. Nov 1987 A
4710192 Liotta et al. Dec 1987 A
4733665 Palmaz Mar 1988 A
4755181 Igoe Jul 1988 A
4759758 Gabbay Jul 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4819751 Shimada et al. Apr 1989 A
4829990 Thuroff et al. May 1989 A
4834755 Silvestrini et al. May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4865600 Carpentier et al. Sep 1989 A
4872874 Taheri Oct 1989 A
4873978 Ginsburg Oct 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4885005 Nashef et al. Dec 1989 A
4909252 Goldberger Mar 1990 A
4917102 Miller et al. Apr 1990 A
4922905 Strecker May 1990 A
4927426 Dretler May 1990 A
4954126 Wallsten Sep 1990 A
4966604 Reiss Oct 1990 A
4969890 Sugita et al. Nov 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
5002556 Ishida et al. Mar 1991 A
5002559 Tower Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5122154 Rhodes Jun 1992 A
5132473 Furutaka et al. Jul 1992 A
5141494 Danforth et al. Aug 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5159937 Tremulis Nov 1992 A
5161547 Tower Nov 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5209741 Spaeth May 1993 A
5215541 Nashef et al. Jun 1993 A
5217481 Barbara Jun 1993 A
5217483 Tower Jun 1993 A
5238004 Sahatjian et al. Aug 1993 A
5258023 Reger Nov 1993 A
5258042 Mehta Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5332402 Teitelbaum Jul 1994 A
5336258 Quintero et al. Aug 1994 A
5350398 Pavcnik et al. Sep 1994 A
5360444 Kusuhara Nov 1994 A
5370685 Stevens Dec 1994 A
5389106 Tower Feb 1995 A
5397351 Pavcnik et al. Mar 1995 A
5409019 Wilk Apr 1995 A
5411552 Andersen et al. May 1995 A
5425739 Jessen Jun 1995 A
5425762 Muller Jun 1995 A
5431676 Dubrul et al. Jul 1995 A
5443446 Shturman Aug 1995 A
5443449 Buelna Aug 1995 A
5443477 Mahn et al. Aug 1995 A
5443495 Buscemi et al. Aug 1995 A
5443499 Schmitt Aug 1995 A
5469868 Reger Nov 1995 A
5476506 Lunn Dec 1995 A
5476510 Eberhardt et al. Dec 1995 A
5480423 Ravenscroft et al. Jan 1996 A
5480424 Cox Jan 1996 A
5489297 Duran Feb 1996 A
5500014 Quijano et al. Mar 1996 A
5507767 Maeda et al. Apr 1996 A
5522881 Lentz Jun 1996 A
5534007 St. Germain et al. Jul 1996 A
5545133 Burns et al. Aug 1996 A
5545209 Roberts et al. Aug 1996 A
5545211 An et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5571215 Sterman et al. Nov 1996 A
5573520 Schwartz et al. Nov 1996 A
5575818 Pinchuk Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5591195 Taheri et al. Jan 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5628784 Strecker May 1997 A
5645559 Hachtman et al. Jul 1997 A
5653745 Trescony et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5667523 Bynon et al. Sep 1997 A
5674277 Freitag Oct 1997 A
5681345 Euteneuer Oct 1997 A
5693083 Baker et al. Dec 1997 A
5693088 Lazarus Dec 1997 A
5693310 Gries et al. Dec 1997 A
5695498 Tower Dec 1997 A
5709713 Evans et al. Jan 1998 A
5713951 Garrison et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson, IV et al. Feb 1998 A
5716417 Girard et al. Feb 1998 A
5720391 Dohm et al. Feb 1998 A
5725549 Lam Mar 1998 A
5728068 Leone et al. Mar 1998 A
5733325 Robinson et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5749890 Shaknovich May 1998 A
5755783 Stobie et al. May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5769882 Fogarty et al. Jun 1998 A
5772609 Nguyen et al. Jun 1998 A
5776188 Shepherd et al. Jul 1998 A
5782904 White et al. Jul 1998 A
5800456 Maeda et al. Sep 1998 A
5800531 Cosgrove et al. Sep 1998 A
5807405 Vanney et al. Sep 1998 A
5817126 Imran Oct 1998 A
5824037 Fogarty et al. Oct 1998 A
5824041 Lenker et al. Oct 1998 A
5824043 Cottone, Jr. Oct 1998 A
5824053 Khosravi et al. Oct 1998 A
5824055 Spiridigliozzi et al. Oct 1998 A
5824056 Rosenberg Oct 1998 A
5824064 Taheri Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5843158 Lenker et al. Dec 1998 A
5843161 Solovay Dec 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5860966 Tower Jan 1999 A
5860996 Urban et al. Jan 1999 A
5861024 Rashidi Jan 1999 A
5861028 Angell Jan 1999 A
5868783 Tower Feb 1999 A
5876419 Carpenter et al. Mar 1999 A
5876448 Thompson et al. Mar 1999 A
5885228 Rosenman et al. Mar 1999 A
5888201 Stinson et al. Mar 1999 A
5891191 Stinson Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5906619 Olson et al. May 1999 A
5907893 Zadno-Azizi et al. Jun 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5944738 Amplatz et al. Aug 1999 A
5954766 Zadno-Azizi et al. Sep 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968070 Bley et al. Oct 1999 A
5984957 Laptewicz, Jr. et al. Nov 1999 A
5984959 Robertson et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6010522 Barbut et al. Jan 2000 A
6015431 Thornton et al. Jan 2000 A
6022370 Tower Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6027525 Suh et al. Feb 2000 A
6042598 Tsugita et al. Mar 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6051014 Jang Apr 2000 A
6059827 Fenton, Jr. May 2000 A
6074418 Buchanan et al. Jun 2000 A
6093203 Uflacker Jul 2000 A
6096074 Pedros Aug 2000 A
6110198 Fogarty et al. Aug 2000 A
6123723 Konya et al. Sep 2000 A
6132473 Williams et al. Oct 2000 A
6139510 Palermo Oct 2000 A
6142987 Tsugita Nov 2000 A
6146366 Schachar Nov 2000 A
6162245 Jayaraman Dec 2000 A
6165200 Tsugita et al. Dec 2000 A
6165209 Patterson et al. Dec 2000 A
6168579 Tsugita Jan 2001 B1
6168614 Andersen et al. Jan 2001 B1
6171327 Daniel et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6187016 Hedges et al. Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6200336 Pavcnik et al. Mar 2001 B1
6206911 Milo Mar 2001 B1
6214036 Letendre et al. Apr 2001 B1
6221006 Dubrul et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6221096 Aiba et al. Apr 2001 B1
6221100 Strecker Apr 2001 B1
6231544 Tsugita et al. May 2001 B1
6231551 Barbut May 2001 B1
6241757 An et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6251135 Stinson et al. Jun 2001 B1
6258114 Konya et al. Jul 2001 B1
6258115 Dubrul Jul 2001 B1
6258120 McKenzie et al. Jul 2001 B1
6258129 Dybdal et al. Jul 2001 B1
6267783 Letendre et al. Jul 2001 B1
6270513 Tsugita et al. Aug 2001 B1
6277555 Duran et al. Aug 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6306164 Kujawski Oct 2001 B1
6309417 Spence et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6319281 Patel Nov 2001 B1
6327772 Zadno-Azizi et al. Dec 2001 B1
6336934 Gilson et al. Jan 2002 B1
6336937 Vonesh et al. Jan 2002 B1
6338735 Stevens Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6348063 Yassour et al. Feb 2002 B1
6352554 De Paulis Mar 2002 B2
6352708 Duran et al. Mar 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6363938 Saadat et al. Apr 2002 B2
6364895 Greenhalgh Apr 2002 B1
6371970 Khosravi et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6379383 Palmaz et al. Apr 2002 B1
6387122 Cragg May 2002 B1
6398807 Chouinard et al. Jun 2002 B1
6402736 Brown et al. Jun 2002 B1
6409750 Hyodoh et al. Jun 2002 B1
6416510 Altman et al. Jul 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468303 Amplatz et al. Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6475239 Campbell et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485501 Green Nov 2002 B1
6485502 Don Michael et al. Nov 2002 B2
6488704 Connelly et al. Dec 2002 B1
6494909 Greenhalgh Dec 2002 B2
6503272 Duerig et al. Jan 2003 B2
6508803 Horikawa et al. Jan 2003 B1
6508833 Pavcnik et al. Jan 2003 B2
6527800 McGuckin, Jr. et al. Mar 2003 B1
6530949 Konya et al. Mar 2003 B2
6530952 Vesely Mar 2003 B2
6537297 Tsugita et al. Mar 2003 B2
6540768 Diaz et al. Apr 2003 B1
6540782 Snyders Apr 2003 B1
6562058 Seguin et al. May 2003 B2
6569196 Vesely May 2003 B1
6572643 Gharibadeh Jun 2003 B1
6585766 Huynh et al. Jul 2003 B1
6592546 Barbut et al. Jul 2003 B1
6592614 Lenker et al. Jul 2003 B2
6605112 Moll et al. Aug 2003 B1
6610077 Hancock et al. Aug 2003 B1
6616682 Joergensen et al. Sep 2003 B2
6622604 Chouinard et al. Sep 2003 B1
6623518 Thompson et al. Sep 2003 B2
6623521 Steinke et al. Sep 2003 B2
6626938 Butaric et al. Sep 2003 B1
6632243 Zadno-Azizi et al. Oct 2003 B1
6635068 Dubrul et al. Oct 2003 B1
6635079 Unsworth et al. Oct 2003 B2
6635080 Lauterjung et al. Oct 2003 B1
6652571 White et al. Nov 2003 B1
6652578 Bailey et al. Nov 2003 B2
6663588 DuBois et al. Dec 2003 B2
6663663 Kim et al. Dec 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6669724 Park et al. Dec 2003 B2
6673089 Yassour et al. Jan 2004 B1
6673109 Cox Jan 2004 B2
6676668 Mercereau et al. Jan 2004 B2
6676692 Rabkin et al. Jan 2004 B2
6676698 McGuckin, Jr. et al. Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers Jan 2004 B2
6685739 DiMatteo et al. Feb 2004 B2
6689144 Gerberding Feb 2004 B2
6689164 Seguin Feb 2004 B1
6692512 Jang Feb 2004 B2
6695864 Macoviak et al. Feb 2004 B2
6695865 Boyle et al. Feb 2004 B2
6702851 Chinn et al. Mar 2004 B1
6712842 Gifford, III et al. Mar 2004 B1
6712843 Elliott Mar 2004 B2
6714842 Ito Mar 2004 B1
6719789 Cox Apr 2004 B2
6723116 Taheri Apr 2004 B2
6729356 Baker et al. May 2004 B1
6730118 Spenser et al. May 2004 B2
6730377 Wang May 2004 B2
6733525 Yang et al. May 2004 B2
6736846 Cox May 2004 B2
6752828 Thornton Jun 2004 B2
6755854 Gillick et al. Jun 2004 B2
6758855 Fulton, III et al. Jul 2004 B2
6764503 Ishimaru Jul 2004 B1
6764509 Chinn et al. Jul 2004 B2
6767345 St. Germain et al. Jul 2004 B2
6769434 Liddicoat et al. Aug 2004 B2
6773454 Wholey et al. Aug 2004 B2
6773456 Gordon et al. Aug 2004 B1
6776791 Stallings et al. Aug 2004 B1
6786925 Schoon et al. Sep 2004 B1
6790229 Berreklouw Sep 2004 B1
6790230 Beyersdorf et al. Sep 2004 B2
6790237 Stinson Sep 2004 B2
6792979 Konya et al. Sep 2004 B2
6797002 Spence et al. Sep 2004 B2
6814746 Thompson et al. Nov 2004 B2
6814754 Greenhalgh Nov 2004 B2
6821297 Snyders Nov 2004 B2
6824041 Grieder et al. Nov 2004 B2
6830585 Artof et al. Dec 2004 B1
6837901 Rabkin et al. Jan 2005 B2
6840957 DiMatteo et al. Jan 2005 B2
6843802 Villalobos et al. Jan 2005 B1
6849085 Marton Feb 2005 B2
6863668 Gillespie et al. Mar 2005 B2
6866650 Stevens et al. Mar 2005 B2
6866669 Buzzard et al. Mar 2005 B2
6872223 Roberts et al. Mar 2005 B2
6872226 Cali et al. Mar 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6881220 Edwin et al. Apr 2005 B2
6887266 Williams et al. May 2005 B2
6890340 Duane May 2005 B2
6893459 Macoviak May 2005 B1
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6905743 Chen et al. Jun 2005 B1
6908481 Cribier Jun 2005 B2
6911036 Douk et al. Jun 2005 B2
6911040 Johnson et al. Jun 2005 B2
6911043 Myers et al. Jun 2005 B2
6936058 Forde et al. Aug 2005 B2
6936067 Buchanan Aug 2005 B2
6939352 Buzzard et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6953332 Kurk et al. Oct 2005 B1
6964673 Tsugita et al. Nov 2005 B2
6969395 Eskuri Nov 2005 B2
6972025 WasDyke Dec 2005 B2
6974464 Quijano et al. Dec 2005 B2
6974474 Pavcnik et al. Dec 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6979350 Moll et al. Dec 2005 B2
6984242 Campbell et al. Jan 2006 B2
6989027 Allen et al. Jan 2006 B2
7004176 Lau Feb 2006 B2
7011681 Vesely Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7025791 Levine et al. Apr 2006 B2
7037331 Mitelberg et al. May 2006 B2
7041132 Quijano et al. May 2006 B2
7044966 Svanidze et al. May 2006 B2
7097658 Oktay Aug 2006 B2
7108715 Lawrence-Brown et al. Sep 2006 B2
7122020 Mogul Oct 2006 B2
7125418 Duran et al. Oct 2006 B2
7141063 White et al. Nov 2006 B2
7147663 Berg et al. Dec 2006 B1
7166097 Barbut Jan 2007 B2
7175652 Cook et al. Feb 2007 B2
7175653 Gaber Feb 2007 B2
7175654 Bonsignore et al. Feb 2007 B2
7175656 Khairkhahan Feb 2007 B2
7189258 Johnson et al. Mar 2007 B2
7191018 Gielen et al. Mar 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7235093 Gregorich Jun 2007 B2
7252682 Seguin Aug 2007 B2
7258696 Rabkin et al. Aug 2007 B2
7261732 Justino Aug 2007 B2
7264632 Wright et al. Sep 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7276078 Spenser et al. Oct 2007 B2
7322932 Xie et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329279 Haug et al. Feb 2008 B2
7331993 White Feb 2008 B2
7374560 Ressemann et al. May 2008 B2
7381219 Salahieh et al. Jun 2008 B2
7381220 Macoviak et al. Jun 2008 B2
7399315 Iobbi Jul 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7470285 Nugent et al. Dec 2008 B2
7491232 Bolduc et al. Feb 2009 B2
7510574 Lê et al. Mar 2009 B2
7524330 Berreklouw Apr 2009 B2
7530995 Quijano et al. May 2009 B2
7544206 Cohn Jun 2009 B2
7622276 Cunanan et al. Nov 2009 B2
7628803 Pavcnik et al. Dec 2009 B2
7632298 Hijlkema et al. Dec 2009 B2
7641687 Chinn et al. Jan 2010 B2
7674282 Wu et al. Mar 2010 B2
7712606 Salahieh et al. May 2010 B2
7722638 Deyette, Jr. et al. May 2010 B2
7722662 Steinke et al. May 2010 B2
7722666 Lafontaine May 2010 B2
7731742 Schlick et al. Jun 2010 B2
7736388 Goldfarb et al. Jun 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7758625 Wu et al. Jul 2010 B2
7780725 Haug et al. Aug 2010 B2
7799065 Pappas Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7824442 Salahieh et al. Nov 2010 B2
7824443 Salahieh et al. Nov 2010 B2
7833262 McGuckin, Jr. et al. Nov 2010 B2
7846204 Letac et al. Dec 2010 B2
7857845 Stacchino et al. Dec 2010 B2
7892292 Stack et al. Feb 2011 B2
7918880 Austin Apr 2011 B2
7938851 Olson et al. May 2011 B2
7959666 Salahieh et al. Jun 2011 B2
7959672 Salahieh et al. Jun 2011 B2
7988724 Salahieh et al. Aug 2011 B2
8048153 Salahieh et al. Nov 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8136659 Salahieh et al. Mar 2012 B2
8157853 Laske et al. Apr 2012 B2
8172896 McNamara et al. May 2012 B2
8182528 Salahieh et al. May 2012 B2
8192351 Fishler et al. Jun 2012 B2
8226710 Nguyen et al. Jul 2012 B2
8231670 Salahieh et al. Jul 2012 B2
8236049 Rowe et al. Aug 2012 B2
8246678 Salahieh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8252052 Salahieh et al. Aug 2012 B2
8287584 Salahieh et al. Oct 2012 B2
8308798 Pintor et al. Nov 2012 B2
8317858 Straubinger et al. Nov 2012 B2
8323335 Rowe et al. Dec 2012 B2
8328868 Paul et al. Dec 2012 B2
8343213 Salahieh et al. Jan 2013 B2
8376865 Forster et al. Feb 2013 B2
8377117 Keidar et al. Feb 2013 B2
8398708 Meiri et al. Mar 2013 B2
8403983 Quadri et al. Mar 2013 B2
8414644 Quadri et al. Apr 2013 B2
8579962 Salahieh et al. Nov 2013 B2
8603160 Salahieh et al. Dec 2013 B2
8617236 Paul et al. Dec 2013 B2
8623074 Ryan Jan 2014 B2
8623076 Salahieh et al. Jan 2014 B2
8623078 Salahieh et al. Jan 2014 B2
8668733 Haug et al. Mar 2014 B2
8696743 Holecek et al. Apr 2014 B2
8778020 Gregg Jul 2014 B2
8828078 Salahieh et al. Sep 2014 B2
8840662 Salahieh et al. Sep 2014 B2
8840663 Salahieh et al. Sep 2014 B2
8858620 Salahieh et al. Oct 2014 B2
8894703 Salahieh et al. Nov 2014 B2
8951299 Paul et al. Feb 2015 B2
8992608 Haug et al. Mar 2015 B2
9005273 Salahieh et al. Apr 2015 B2
9011521 Haug et al. Apr 2015 B2
9168131 Yohanan et al. Oct 2015 B2
9474598 Gregg Oct 2016 B2
9700411 Klima Jul 2017 B2
20010002445 Vesely May 2001 A1
20010007956 Letac et al. Jul 2001 A1
20010010017 Letac et al. Jul 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025196 Chinn et al. Sep 2001 A1
20010027338 Greenberg Oct 2001 A1
20010032013 Marton Oct 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010041928 Pavcnik et al. Nov 2001 A1
20010041930 Globerman et al. Nov 2001 A1
20010044634 Don Michael et al. Nov 2001 A1
20010044652 Moore Nov 2001 A1
20010044656 Williamson, IV et al. Nov 2001 A1
20020002396 Fulkerson Jan 2002 A1
20020010489 Grayzel et al. Jan 2002 A1
20020026233 Shaknovich Feb 2002 A1
20020029014 Jayaraman Mar 2002 A1
20020029981 Nigam Mar 2002 A1
20020032480 Spence et al. Mar 2002 A1
20020032481 Gabbay Mar 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020052651 Myers et al. May 2002 A1
20020055767 Forde et al. May 2002 A1
20020055769 Wang May 2002 A1
20020055774 Liddicoat May 2002 A1
20020058987 Butaric et al. May 2002 A1
20020058995 Stevens May 2002 A1
20020077696 Zadno-Azizi et al. Jun 2002 A1
20020082609 Green Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020095209 Zadno-Azizi et al. Jul 2002 A1
20020111674 Chouinard et al. Aug 2002 A1
20020120328 Pathak et al. Aug 2002 A1
20020123802 Snyders Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020151970 Garrison et al. Oct 2002 A1
20020156522 Ivancev et al. Oct 2002 A1
20020161390 Mouw Oct 2002 A1
20020161392 Dubrul Oct 2002 A1
20020161394 Macoviak et al. Oct 2002 A1
20020165576 Boyle et al. Nov 2002 A1
20020177766 Mogul Nov 2002 A1
20020183781 Casey et al. Dec 2002 A1
20020188341 Elliott Dec 2002 A1
20020188344 Bolea et al. Dec 2002 A1
20020193871 Beyersdorf et al. Dec 2002 A1
20030014104 Cribier Jan 2003 A1
20030023303 Palmaz et al. Jan 2003 A1
20030028247 Cali Feb 2003 A1
20030036791 Philipp et al. Feb 2003 A1
20030040736 Stevens et al. Feb 2003 A1
20030040771 Hyodoh et al. Feb 2003 A1
20030040772 Hyodoh et al. Feb 2003 A1
20030040791 Oktay Feb 2003 A1
20030040792 Gabbay Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060844 Borillo et al. Mar 2003 A1
20030069492 Abrams et al. Apr 2003 A1
20030069646 Stinson Apr 2003 A1
20030070944 Nigam Apr 2003 A1
20030074058 Sherry Apr 2003 A1
20030093145 Lawrence-Brown et al. May 2003 A1
20030100918 Duane May 2003 A1
20030100919 Hopkins et al. May 2003 A1
20030109924 Cribier Jun 2003 A1
20030109930 Bluni et al. Jun 2003 A1
20030114912 Sequin et al. Jun 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030125795 Pavcnik et al. Jul 2003 A1
20030130729 Paniagua et al. Jul 2003 A1
20030135257 Taheri Jul 2003 A1
20030144732 Cosgrove et al. Jul 2003 A1
20030149475 Hyodoh et al. Aug 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030149478 Figulla et al. Aug 2003 A1
20030153974 Spenser et al. Aug 2003 A1
20030165352 Ibrahim et al. Sep 2003 A1
20030171803 Shimon Sep 2003 A1
20030176884 Berrada et al. Sep 2003 A1
20030181850 Diamond et al. Sep 2003 A1
20030187495 Cully et al. Oct 2003 A1
20030191516 Weldon et al. Oct 2003 A1
20030195609 Berenstein et al. Oct 2003 A1
20030195620 Huynh Oct 2003 A1
20030199759 Richard Oct 2003 A1
20030199913 Dubrul et al. Oct 2003 A1
20030199971 Tower et al. Oct 2003 A1
20030199972 Zadno-Azizi et al. Oct 2003 A1
20030204249 Letort Oct 2003 A1
20030208224 Broome Nov 2003 A1
20030212429 Keegan et al. Nov 2003 A1
20030212452 Zadno-Azizi et al. Nov 2003 A1
20030212454 Scott et al. Nov 2003 A1
20030216774 Larson Nov 2003 A1
20030225445 Derus et al. Dec 2003 A1
20030229390 Ashton et al. Dec 2003 A1
20030233117 Adams et al. Dec 2003 A1
20030236567 Elliot Dec 2003 A1
20040019374 Hojeibane et al. Jan 2004 A1
20040033364 Spiridigliozzi et al. Feb 2004 A1
20040034411 Quijano et al. Feb 2004 A1
20040039436 Spenser et al. Feb 2004 A1
20040049224 Buehlmann et al. Mar 2004 A1
20040049226 Keegan et al. Mar 2004 A1
20040049262 Obermiller et al. Mar 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040059409 Stenzel Mar 2004 A1
20040073198 Gilson et al. Apr 2004 A1
20040082904 Houde et al. Apr 2004 A1
20040082967 Broome et al. Apr 2004 A1
20040082989 Cook et al. Apr 2004 A1
20040087982 Eskuri May 2004 A1
20040088045 Cox May 2004 A1
20040093016 Root et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040097788 Mourlas et al. May 2004 A1
20040098022 Barone May 2004 A1
20040098098 McGuckin, Jr. et al. May 2004 A1
20040098099 McCullagh et al. May 2004 A1
20040098112 DiMatteo et al. May 2004 A1
20040107004 Levine et al. Jun 2004 A1
20040111096 Tu et al. Jun 2004 A1
20040116951 Rosengart Jun 2004 A1
20040116999 Ledergerber Jun 2004 A1
20040117004 Osborne et al. Jun 2004 A1
20040117009 Cali et al. Jun 2004 A1
20040122468 Yodfat et al. Jun 2004 A1
20040122516 Fogarty et al. Jun 2004 A1
20040127936 Salahieh et al. Jul 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040133274 Webler et al. Jul 2004 A1
20040138694 Tran et al. Jul 2004 A1
20040138742 Myers et al. Jul 2004 A1
20040138743 Myers et al. Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040148021 Cartledge et al. Jul 2004 A1
20040153094 Dunfee et al. Aug 2004 A1
20040158277 Lowe et al. Aug 2004 A1
20040167565 Beulke et al. Aug 2004 A1
20040167620 Ortiz et al. Aug 2004 A1
20040181140 Falwell et al. Sep 2004 A1
20040186558 Pavcnik et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040193261 Berreklouw Sep 2004 A1
20040197695 Aono Oct 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040204755 Robin Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040210306 Quijano et al. Oct 2004 A1
20040210307 Khairkhahan Oct 2004 A1
20040215331 Chew et al. Oct 2004 A1
20040215333 Duran et al. Oct 2004 A1
20040215339 Drasler et al. Oct 2004 A1
20040220655 Swanson et al. Nov 2004 A1
20040225321 Krolik et al. Nov 2004 A1
20040225352 Osborne Nov 2004 A1
20040225353 McGuckin, Jr. et al. Nov 2004 A1
20040225354 Allen et al. Nov 2004 A1
20040225355 Stevens Nov 2004 A1
20040243221 Fawzi et al. Dec 2004 A1
20040254636 Flagle et al. Dec 2004 A1
20040260390 Sarac et al. Dec 2004 A1
20050010287 Macoviak et al. Jan 2005 A1
20050021136 Xie et al. Jan 2005 A1
20050027348 Case Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050033402 Cully et al. Feb 2005 A1
20050043711 Corcoran et al. Feb 2005 A1
20050043757 Arad et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050049692 Numamoto et al. Mar 2005 A1
20050049696 Siess et al. Mar 2005 A1
20050055088 Liddicoat et al. Mar 2005 A1
20050060016 Wu et al. Mar 2005 A1
20050060029 Le et al. Mar 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075662 Pedersen et al. Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075717 Nguyen et al. Apr 2005 A1
20050075719 Bergheim Apr 2005 A1
20050075724 Svanidze et al. Apr 2005 A1
20050075730 Myers et al. Apr 2005 A1
20050075731 Artof et al. Apr 2005 A1
20050085841 Eversull et al. Apr 2005 A1
20050085842 Eversull et al. Apr 2005 A1
20050085843 Opolski et al. Apr 2005 A1
20050085890 Rasmussen et al. Apr 2005 A1
20050090846 Pedersen et al. Apr 2005 A1
20050090890 Wu et al. Apr 2005 A1
20050096692 Linder et al. May 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096735 Hojeibane et al. May 2005 A1
20050096736 Osse et al. May 2005 A1
20050096738 Cali et al. May 2005 A1
20050100580 Osborne et al. May 2005 A1
20050107822 Wasdyke May 2005 A1
20050113910 Paniagua et al. May 2005 A1
20050131438 Cohn Jun 2005 A1
20050137683 Hezi-Yamit et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137692 Haug et al. Jun 2005 A1
20050137693 Haug et al. Jun 2005 A1
20050137694 Haug et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137697 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050137702 Haug et al. Jun 2005 A1
20050138689 Aukerman Jun 2005 A1
20050143807 Pavcnik et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050149159 Andreas et al. Jul 2005 A1
20050165352 Henry et al. Jul 2005 A1
20050165477 Anduiza et al. Jul 2005 A1
20050165479 Drews et al. Jul 2005 A1
20050182486 Gabbay Aug 2005 A1
20050197694 Pai et al. Sep 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203549 Realyvasquez Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203616 Cribier Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050203618 Sharkawy et al. Sep 2005 A1
20050203818 Rotman et al. Sep 2005 A9
20050209580 Freyman Sep 2005 A1
20050228472 Case et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050240262 White Oct 2005 A1
20050251250 Verhoeven et al. Nov 2005 A1
20050251251 Cribier Nov 2005 A1
20050261759 Lambrecht et al. Nov 2005 A1
20050267560 Bates Dec 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050283962 Boudjemline Dec 2005 A1
20060004439 Spenser et al. Jan 2006 A1
20060004442 Spenser et al. Jan 2006 A1
20060015168 Gunderson Jan 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060149360 Schwammenthal et al. Jul 2006 A1
20060155312 Levine et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060173524 Salahieh et al. Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060253191 Salahieh et al. Nov 2006 A1
20060259134 Schwammenthal et al. Nov 2006 A1
20060271166 Thill et al. Nov 2006 A1
20060287668 Fawzi et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070010876 Salahieh et al. Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070055340 Pryor Mar 2007 A1
20070061008 Salahieh et al. Mar 2007 A1
20070112355 Salahieh et al. May 2007 A1
20070118214 Salahieh et al. May 2007 A1
20070162107 Haug et al. Jul 2007 A1
20070173918 Dreher et al. Jul 2007 A1
20070203503 Salahieh et al. Aug 2007 A1
20070244552 Salahieh et al. Oct 2007 A1
20070288089 Gurskis et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033541 Gelbart et al. Feb 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080082165 Wilson et al. Apr 2008 A1
20080125859 Salahieh et al. May 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080234814 Salahieh et al. Sep 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080269878 Iobbi Oct 2008 A1
20080288054 Pulnev et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090030512 Thielen et al. Jan 2009 A1
20090054969 Salahieh et al. Feb 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090093877 Keidar et al. Apr 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090216312 Straubinger et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090264759 Byrd Oct 2009 A1
20090264997 Salahieh et al. Oct 2009 A1
20090299462 Fawzi et al. Dec 2009 A1
20100023120 Holecek Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082089 Quadri et al. Apr 2010 A1
20100094399 Dorn et al. Apr 2010 A1
20100121434 Paul et al. May 2010 A1
20100161045 Righini Jun 2010 A1
20100185275 Richter et al. Jul 2010 A1
20100191320 Straubinger et al. Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100219092 Salahieh et al. Sep 2010 A1
20100249908 Chau et al. Sep 2010 A1
20100280495 Paul et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110257735 Salahieh et al. Oct 2011 A1
20110264196 Savage et al. Oct 2011 A1
20110276122 Schlick Nov 2011 A1
20110276129 Salahieh et al. Nov 2011 A1
20110288634 Tuval et al. Nov 2011 A1
20110295363 Girard et al. Dec 2011 A1
20120016469 Salahieh et al. Jan 2012 A1
20120016471 Salahieh et al. Jan 2012 A1
20120022642 Haug et al. Jan 2012 A1
20120029627 Salahieh et al. Feb 2012 A1
20120041549 Salahieh et al. Feb 2012 A1
20120041550 Salahieh et al. Feb 2012 A1
20120046740 Paul et al. Feb 2012 A1
20120053683 Salahieh et al. Mar 2012 A1
20120089224 Haug et al. Apr 2012 A1
20120132547 Salahieh et al. May 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120197379 Laske et al. Aug 2012 A1
20120303113 Benichou et al. Nov 2012 A1
20120303116 Gorman et al. Nov 2012 A1
20120330409 Haug et al. Dec 2012 A1
20130013057 Salahieh et al. Jan 2013 A1
20130018457 Gregg et al. Jan 2013 A1
20130030520 Lee et al. Jan 2013 A1
20130079867 Hoffman et al. Mar 2013 A1
20130079869 Straubinger et al. Mar 2013 A1
20130096664 Goetz et al. Apr 2013 A1
20130116778 Gregg May 2013 A1
20130123796 Sutton et al. May 2013 A1
20130138207 Quadri et al. May 2013 A1
20130158656 Sutton et al. Jun 2013 A1
20130184813 Quadri et al. Jul 2013 A1
20130190865 Anderson Jul 2013 A1
20130304199 Sutton et al. Nov 2013 A1
20140018911 Zhou et al. Jan 2014 A1
20140094904 Salahieh et al. Apr 2014 A1
20140114405 Paul et al. Apr 2014 A1
20140114406 Salahieh et al. Apr 2014 A1
20140121766 Salahieh et al. May 2014 A1
20140135912 Salahieh et al. May 2014 A1
20140243967 Salahieh et al. Aug 2014 A1
20140277428 Skemp et al. Sep 2014 A1
20150012085 Salahieh et al. Jan 2015 A1
20150073540 Salahieh et al. Mar 2015 A1
20150073541 Salahieh et al. Mar 2015 A1
20150081000 Hossainy Mar 2015 A1
20150127094 Salahieh et al. May 2015 A1
20150134043 Irwin May 2015 A1
20160045307 Yohanan et al. Feb 2016 A1
20160106538 Mitra Apr 2016 A1
20160199184 Ma et al. Jul 2016 A1
20160256268 Dakin Sep 2016 A1
20160296329 Alkhatib Oct 2016 A1
Foreign Referenced Citations (173)
Number Date Country
2002329324 Jul 2007 AU
1338951 Mar 2002 CN
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049814 Apr 2002 DE
10049815 Apr 2002 DE
0103546 May 1988 EP
0144167 Nov 1989 EP
579523 Jan 1994 EP
0409929 Apr 1997 EP
0850607 Jul 1998 EP
0597967 Dec 1999 EP
1000590 May 2000 EP
1057459 Dec 2000 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
0937439 Sep 2003 EP
1340473 Sep 2003 EP
1356793 Oct 2003 EP
1042045 May 2004 EP
0819013 Jun 2004 EP
1430853 Jun 2004 EP
1435879 Jul 2004 EP
1439800 Jul 2004 EP
1472996 Nov 2004 EP
1229864 Apr 2005 EP
1059894 Jul 2005 EP
1551274 Jul 2005 EP
1551336 Jul 2005 EP
1078610 Aug 2005 EP
1562515 Aug 2005 EP
1570809 Sep 2005 EP
1576937 Sep 2005 EP
1582178 Oct 2005 EP
1582179 Oct 2005 EP
1469797 Nov 2005 EP
1589902 Nov 2005 EP
1600121 Nov 2005 EP
1156757 Dec 2005 EP
1616531 Jan 2006 EP
1605871 Jul 2008 EP
2749254 Jun 2015 EP
2926766 Oct 2015 EP
2788217 Jul 2000 FR
2056023 Mar 1981 GB
2398245 Aug 2004 GB
1271508 Nov 1986 SU
1371700 Feb 1988 SU
9117720 Nov 1991 WO
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9315693 Aug 1993 WO
9504556 Feb 1995 WO
9529640 Nov 1995 WO
9614032 May 1996 WO
9624306 Aug 1996 WO
9640012 Dec 1996 WO
9748350 Dec 1997 WO
9829057 Jul 1998 WO
9836790 Aug 1998 WO
9850103 Nov 1998 WO
9855047 Dec 1998 WO
9857599 Dec 1998 WO
9933414 Jul 1999 WO
9940964 Aug 1999 WO
9944542 Sep 1999 WO
9947075 Sep 1999 WO
9951165 Oct 1999 WO
0009059 Feb 2000 WO
2000009059 Feb 2000 WO
0041652 Jul 2000 WO
0044308 Aug 2000 WO
0044311 Aug 2000 WO
0044313 Aug 2000 WO
0045874 Aug 2000 WO
0047139 Aug 2000 WO
0049970 Aug 2000 WO
0067661 Nov 2000 WO
0105331 Jan 2001 WO
0106959 Feb 2001 WO
0108596 Feb 2001 WO
0110320 Feb 2001 WO
0110343 Feb 2001 WO
0135870 May 2001 WO
0149213 Jul 2001 WO
0154625 Aug 2001 WO
0162189 Aug 2001 WO
2001054625 Aug 2001 WO
0164137 Sep 2001 WO
0176510 Oct 2001 WO
0197715 Dec 2001 WO
0236048 May 2002 WO
0241789 May 2002 WO
0243620 Jun 2002 WO
0247575 Jun 2002 WO
02056955 Jul 2002 WO
02069842 Sep 2002 WO
02100297 Dec 2002 WO
03003943 Jan 2003 WO
03003949 Jan 2003 WO
03011195 Feb 2003 WO
03028592 Apr 2003 WO
03030776 Apr 2003 WO
03032869 Apr 2003 WO
03037222 May 2003 WO
03037227 May 2003 WO
03047468 Jun 2003 WO
03047648 Jun 2003 WO
03088873 Oct 2003 WO
03015851 Nov 2003 WO
03094793 Nov 2003 WO
03094797 Nov 2003 WO
03096932 Nov 2003 WO
2004006803 Jan 2004 WO
2004006804 Jan 2004 WO
2004014256 Feb 2004 WO
2004019811 Mar 2004 WO
2004019817 Mar 2004 WO
2004021922 Mar 2004 WO
2004023980 Mar 2004 WO
2004026117 Apr 2004 WO
2004041126 May 2004 WO
2004043293 May 2004 WO
2004047681 Jun 2004 WO
2004058106 Jul 2004 WO
2004066876 Aug 2004 WO
2004082536 Sep 2004 WO
2004089250 Oct 2004 WO
2004089253 Oct 2004 WO
2004093728 Nov 2004 WO
2004105651 Dec 2004 WO
2005002466 Jan 2005 WO
2005004753 Jan 2005 WO
2005009285 Feb 2005 WO
2005011534 Feb 2005 WO
2005011535 Feb 2005 WO
2005023155 Mar 2005 WO
2005027790 Mar 2005 WO
2005046528 May 2005 WO
2005046529 May 2005 WO
2005048883 Jun 2005 WO
2005062980 Jul 2005 WO
2005065585 Jul 2005 WO
2005084595 Sep 2005 WO
2005087140 Sep 2005 WO
2005096993 Oct 2005 WO
2006005015 Jan 2006 WO
2006009690 Jan 2006 WO
2006027499 Mar 2006 WO
2006138391 Dec 2006 WO
2007033093 Mar 2007 WO
2007035471 Mar 2007 WO
2005102015 Apr 2007 WO
2007044285 Apr 2007 WO
2007053243 May 2007 WO
2007058847 May 2007 WO
2007092354 Aug 2007 WO
2007097983 Aug 2007 WO
2010042950 Apr 2010 WO
2010098857 Sep 2010 WO
2012116368 Aug 2012 WO
2012162228 Nov 2012 WO
2013009975 Jan 2013 WO
2013028387 Feb 2013 WO
2013074671 May 2013 WO
2013096545 Jun 2013 WO
2014140230 Sep 2014 WO
2014164151 Oct 2014 WO
2016126511 Aug 2016 WO
Non-Patent Literature Citations (139)
Entry
US 8,062,356, 11/2011, Salahieh et al. (withdrawn)
US 8,062,357, 11/2011, Salahieh et al. (withdrawn)
US 8,075,614, 12/2011, Salahieh et al. (withdrawn)
US 8,133,271, 03/2012, Salahieh et al. (withdrawn)
US 8,211,170, 07/2012, Paul et al. (withdrawn)
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, 1992.
Atwood et al., “Insertation of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40.
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation. New York, 1991: 307-322.
Boudjemline et al. “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, 2002.
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., 23: 1045-1049, 2002.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, 2004.
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, 2003.
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, 2002.
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, 2004.
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.” Circulation, 106: 3006-3008, 2002.
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, 2002.
Ferrari et al., “Percutaneous Transvascular Aortic Valve Replacement with Self-Expanding Stent-Valve Device.” Poster from the presentation given at SMIT 2000, 12th International Conference. Sep. 5, 2000.
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, 2004.
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, 2004.
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am. Heart J., 142(3): 476-481, 2001.
Love et al., The Autogenous Tissue Heart Valve: Current Status. Journal of Cardiac Surgery, 6(4): 499-507, 1991.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, 2002.
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11(5): 423-430, 1971.
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, 2002.
Paniagua et al., “Heart Watch.” Texas Heart Institute. Spring, 2004. Edition: 8 pages.
Pavcnik et al., “Percutaneous Bioprosthetic Veno Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, 2002.
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, 1976.
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent. Radiol., 23: 384-388, 2000.
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. 9-17, 2004.
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, 2004.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, 2002.
Zhou et al, “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, 2003.
Examiner's First Report on AU Patent Application No. 2011202667, dated May 17, 2012.
“A Matter of Size.” Treiennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, 2006, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology.
Atwood et al., “Insertion of Heart Valves by Catheterization.” The Capstone Design Course Report. MIME 1501-1502. Technical Design Report. Northeastern University, pp. 1-93, Nov. 5, 2007.
Aug. 19, 2011, Supplemental Search Report from EP Patent Office, EP Application No. 04813777.2.
Aug. 19, 2011, Supplemental Search Report from EP Patent Office, EP Application No. 04815634.3.
Cunanan et al., “Tissue Characterization and Calcification Potential of Commerical Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S417-421, 2001.
Cunliffe et al., “Glutaraldehyde Inactivation of Exotic Animal Viruses in Swine Heart Tissue.” Applied and Environmental Microbiology, Greenport, New York, 37(5): 1044-1046, May 1979.
EP Search Report dated Aug. 10, 2011 for EP Application No. 06824992.9.
“Heart Valve Materials—Bovine (cow).” Equine & Porcine Pericardium, Maverick Biosciences Pty. Lt, http://maverickbio.com/biological-medical-device-materials.php?htm. 2009.
Helmus, “Mechanical and Bioprosthetic Heart Valves in Biomaterials for Artificial Organs.” Woodhead Publishing Limited: 114-162, 2011.
Hourihan et al., “Transcatheter Umbrella Closure of Valvular and Paravalvular Leaks.” JACC, Boston, Massachusetts, 20(6): 1371-1377, Nov. 15, 1992.
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, 2006.
Levy, “Mycobacterium chelonei Infection of Porcine Heart Valves.” The New England Journal of Medicine, Washington DC, 297(12), Sep. 22, 1977.
Supplemental Search Report from EP Patent Office, EP Application No. 05758878.2, dated Oct. 24, 2011.
“Pericardial Heart Valves.” Edwards Lifesciences, Cardiovascular Surgery FAQ, Nov. 14, 2010, http://www.edwards.com/products/cardiovascularsurgeryfaq.htm.
Southern Lights Biomaterials Homepage, Jan. 7, 2011, http://www.slv.co.nz/.
Stassano. “Mid-term Results of the Valve-on-Valve Technique for Bioprosthetic Failure.” European Journal of Cardiothoracic Surgery: 453-457, 2000.
Topol. “Percutaneous Expandable Prosthetic Valves.” Textbook of Interventional Cardiology, W.B. Saunders Company, 2: 1268-1276, 1994.
International Search Report and Written Opinion PCT/US2016/6015445, dated Jun. 30, 2016.
Andersen et al., “Transluminal implantation of artificial heart valves. Description of a new expandable aortic valve and initial results with implantation by catheter technique in closed chest pigs.” Euro. Heart J., 13:704-708, May 1992.
Atwood et al., “Insertion of Heart Valves by Catheterization.” Project Supervised by Prof. S. Muftu of Northeastern University 2001-2002: 36-40, May 30, 2002.
Bodnar et al., “Replacement Cardiac Valves R Chapter 13: Extinct Cardiac Valve Prostheses.” Pergamon Publishing Corporation. New York, 307-322, 1991.
Boudjemline et al. “Percutaneous Implantation of a Biological Valve in the Aorta to Treat Aortic Valve Insufficiency—A Sheep Study.” Med Sci. Monit., vol. 8, No. 4: BR113-116, Apr. 12, 2002.
Boudjemline et al., “Percutaneous Implantation of a Valve in the Descending Aorta in Lambs.” Euro. Heart J., 23: 1045-1049, Jul. 2002.
Boudjemline et al., “Percutaneous Pulmonary Valve Replacement in a Large Right Ventricular Outflow Tract: An Experimental Study.” Journal of the American College of Cardiology, vol. 43(6): 1082-1087, Mar. 17, 2004.
Boudjemline et al., “Percutaneous Valve Insertion: A New Approach?” J. of Thoracic and Cardio. Surg, 125(3): 741-743, Mar. 2003.
Boudjemline et al., “Steps Toward Percutaneous Aortic Valve Replacement.” Circulation, 105: 775-778, Feb. 12, 2002.
Cribier et al., “Early Experience with Percutaneous Transcatheter Implantation of Heart Valve Prosthesis for the Treatment of End-Stage Inoperable Patients with Calcific Aortic Stenosis.” J. of Am. Coll. of Cardio, 43(4): 698-703, Feb. 18, 2004.
Cribier et al., “Percutaneous Transcatheter Implementation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case Description.” Circulation, 106: 3006-3008, Dec. 10, 2002.
Cribier et al., “Percutaneous Transcatheter Implantation of an Aortic Valve Prosthesis for Calcific Aortic Stenosis: First Human Case.” Percutaneous Valve Technologies, Inc., 16 pages, Apr. 16, 2002.
Hijazi, “Transcatheter Valve Replacement: A New Era of Percutaneous Cardiac Intervention Begins.” J. of Am. College of Cardio., 43(6): 1088-1089, Mar. 17, 2004.
Huber et al., “Do Valved Stents Compromise Coronary Flow?” European Journal of Cardio-thoracic Surgery, vol. 25: 754-759, Jan. 23, 2004.
Knudsen et al., “Catheter-implanted prosthetic heart valves.” Int'l J. of Art. Organs, 16(5): 253-262, May 1993.
Kort et al., “Minimally Invasive Aortic Valve Replacement: Echocardiographic and Clinical Results.” Am. Heart J., 142(3): 476-481, Sep. 2001.
Love et al., The Autogenous Tissue Heart Valve: Current Status. Journal of Cardiac Surgery, 6(4): 499-507, Mar. 1991.
Lutter et al., “Percutaneous Aortic Valve Replacement: An Experimental Study. I. Studies on Implantation.” J. of Thoracic and Cardio. Surg., 123(4): 768-776, Apr. 2002.
Moulopoulos et al., “Catheter-Mounted Aortic Valves.” Annals of Thoracic Surg., 11(5): 423-430, May 1971.
Paniagua et al., “Percutaneous Heart Valve in the Chronic in Vitro Testing Model.” Circulation, 106: e51-e52, Sep. 17, 2002.
Paniagua et al., “Heart Watch.” Texas Heart Institute. Edition: 8 pages, Spring, 2004.
Pavcnik et al., “Percutaneous Bioprosthetic Venous Valve: A Long-term Study in Sheep.” J. of Vascular Surg., 35(3): 598-603, Mar. 2002.
Phillips et al., “A Temporary Catheter-Tip Aortic Valve: Hemodynamic Effects on Experimental Acute Aortic Insufficiency.” Annals of Thoracic Surg., 21(2): 134-136, Feb. 1976.
Sochman et al., “Percutaneous Transcatheter Aortic Disc Valve Prosthesis Implantation: A Feasibility Study.” Cardiovasc. Intervent. Radiol., 23: 384-388, Sep. 2000.
Stuart, “In Heart Valves, A Brave, New Non-Surgical World.” Start-Up. Feb. 9-17, 2004.
Stassano. “Mid-term Results of the Valve-on-Valve Technique for Bioprosthetic Failure.” European Journal of Cardiothoracic Surgery: vol. 18, 453-457, Oct. 2000.
“A Matter of Size.” Triennial Review of the National Nanotechnology Initiative, The National Academies Press, Washington DC, v-13, http://www.nap.edu/catalog/11752/a-matter-of-size-triennial-review-of-the-national-nanotechnology, 2006.
Cunanan et al., “Tissue Characterization and Calcification Potential of Commercial Bioprosthetic Heart Valves.” Ann. Thorac. Surg., S417-421, May 15, 2001.
Laborde et al., “Percutaneous Implantation of the Corevalve Aortic Valve Prosthesis for Patients Presenting High Risk for Surgical Valve Replacement.” EuroIntervention: 472-474, Feb. 2006.
Vahanian et al., “Percutaneous Approaches to Valvular Disease.” Circulation, 109: 1572-1579, Apr. 6, 2004.
Van Herwerden et al., “Percutaneous Valve Implantation: Back to the Future?” Euro. Heart J., 23(18): 1415-1416, Sep. 2002.
Zhou et al, “Self-expandable Valved Stent of Large Size: Off-Bypass Implantation in Pulmonary Position.” Eur. J. Cardiothorac, 24: 212-216, Aug. 2003.
Yoshioka et al., “Self-Expanding Endovascular Graft: An Experimental Study in Dogs.” AJR 151: 673-76 (Oct. 1988).
USPTO Case IPR2017-01293, U.S. Pat. No. 8,992,608 B, Oct. 13, 2017.
USPTO Case IPR2016-, U.S. Pat. No. 8,992,608 “Petition for Interpartes Review of U.S. Pat. No. 8,992,608” Oct. 12, 2016.
USPTO Case IPR 2017-0006, U.S. Pat. No. 8,992,608 B2, “Final Written Decision” Mar. 23, 2018.
Fluency Vascular Stent Graft Instructions for Use (2003).
Carpentier-Edwards PERIMOUNT Bioprosthesis (2003).
Cribier et al., “Percutaneous Transluminal Valvuloplasty of Acquired Aortic Stenosis in Elderly Patients: An Alternative to Valve Replacement?” The Lancet, 63-7 (Jan. 11, 1986).
Allen et al., “What are the characteristics of the ideal endovascular graft for abdominal aortic aneurysm exclusion?” J. Endovasc. Surg., 4(2):195-202 (May 1997).
Andersen et al. “Transluminal catheter implantation of a new expandable artificial cardiac valve (the stent—valve) in the aorta and the beating heart of closed chest pigs (Abstract).” Eur. Heart J., 11 (Suppl.): 224a (1990).
Bailey, “Percutaneous Expandable Prosthetic Valves, Textbook of Interventional Cardiology.” vol. 2, 2d ed. Eric J. Topol, W.B. Saunders Co. (1994).
Blum et al., “Endoluminal Stent—Grafts for Intrarenal Abdominal Aortic Aneurysms.” New Engl. J. Med., 336:13-20 (1997).
Bonhoeffer et al., “Percutaneous Insertion of the Pulmonary Valve.” J. Am. Coll. Cardiol., 39:1664-9 (2002).
Bonhoeffer et al., “Transcatheter Implantation of a Bovine Valve in Pulmonary Position: A Lamb Study.” Circulation, 102: 813-16 (2000).
Bonhoeffer, et al., “Percutaneous replacement of pulmonary valve in a right ventricle to pulmonary-artery prosthetic conduit with valve dysfunction.” The Lancet, vol. 356, 1403-05 (Oct. 21, 2000).
Couper, “Surgical Aspects of Prosthetic Valve Selection,” Overview of Cardiac Surgery for the Cardiologist, Springer-Verlag New York, Inc., 131-145 (1994).
Cribier et al., “Trans-Cathether Implantation of Balloon-Expandable Prosthetic Heart Valves: Early Results in an Animal Model.” Circulation [suppl. II] 104(17)II-552 (Oct. 23, 2001).
Dake et al., “Transluminal Placement of Endovascular Stent-Grafts for the Treatment of Descending Thoracic Aortic Aneurysms.” New Engl. J. of Med., 331(26):1729-34 (1994).
Dalby et al., “Non-Surgical Aortic Valve Replacement” Br. J. Cardiol., 10:450-2 (2003).
Dhasmana, et al., “Factors Associated With Periprosthetic Leakage Following Primary Mitral Valve Replacement: With Special Consideration of Suture Technique.” Annals of Thorac. Surg. 35(2), 170-8 (Feb. 1983).
Diethrich, AAA Stent Grafts: Current Developments, J. Invasive Cardiol. 13(5) (2001).
Dolmatch et al., Stent Grafts: Current Clinical Practice (2000)—EVT Endograft and Talent Endoprosthesis.
Dotter, “Transluminally-Placed Coilspring Endarterial Tube Grafts,” Investigative Radiology, pp. 329-332 (1969).
Emery et al., “Replacement of the Aortic Valve in Patients Under 50 Years of Age: Long-Term Follow-Up of the St. Jude Medical Prosthesis.” Ann. Thorac. Surg., 75:1815-9 (2003).
Gore Excluder Instructions for Use (2002).
Greenberg, “Abdominal Aortic Endografting: Fixation and Sealing.” J. Am. Coll. Surg. 194:1:S79-S87 (2002).
Grossi, “Impact of Minimally Invasive Valvular Heart Surgery: A Case-Control Study.” Ann. Thorac. Surg., 71:807-10 (2001).
Ing, “Stents: What's Available to the Pediatric Interventional Cardiologist?” Catheterization and Cardiovascular Interventions 57:274-386 (2002).
Ionescu, et al., “Prevalence and Clinical Significance of Incidental Paraprosthetic Valvar Regurgitation: A prospective study using transesophageal echocardiography.” Heart, 89:1316-21 (2003).
Kaiser, et al., “Surgery for Left Ventricle Outflow Obstruction: Aortic Valve Replacement and Myomectomy,” Overview of Cardiac Surgery for the Cardiologist. Springer-Verlag New York, Inc., 40-45 (1994).
Kato et al., “Traumatic Thoracic Aortic Aneurysm: Treatment with Endovascular Stent-Grafts.” Radiol., 205: 657-662 (1997).
Khonsari et al., “Cardiac Surgery: Safeguards and Pitfalls in Operative Technique.” 3d ed., 45-74 (2003).
Lawrence et al., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 163(2): 357-60 (May 1987).
Levi et al., “Future of Interventional Cardiology in Pediactrics.” Current Opinion in Cardiol., 18:79-90 (2003).
Magovern et al., “Twenty-five-Year Review of the Magovern-Cromie Sutureless Aortic Valve.” Ann. Thorac. Surg., 48: S33-4 (1989).
Maraj et al., Evaluation of Hemolysis in Patients with Prosthetic Heart Valves, Clin. Cardiol. 21, 387-392 (1998).
McKay et al., “The Mansfield Scientific Aortic Valvuloplasty Registry: Overview of Acute Hemodynamic Results and Procedural Complications.” J. Am. Coll. Cardiol. 17(2): 485-91 (Feb. 1991).
Mirich et al., “Percutaneously Placed Endovascular Grafts for Aortic Aneurysms: Feasibility Study.” Radiology, 170: 1033-1037 (1989).
Moazami et al., “Transluminal Aortic Valve Placement: A Feasibility Study With a Newly Designed Collapsiable Aortic Valve,” ASAIO J. vol. 42:5, pp. M383-85 (Sep./Oct. 1996).
Parodi et al., “Transfemoral Intraluminal Graft Implantation for Abdominal Aortic Aneurysms.” Ann. Vasc. Surg., 5 (6):491-9 (1991).
Pavcnik et al., “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement.” Radiology 183:151-54 (1992).
Pavcnik, et al., “Aortic and venous valve for percutaneous insertion,” Min. Invas. Ther. & Allied Technol. 9(3/4) 287-292 (2000).
Printz, et al., “Let the Blood Circulate.” Sulzer Tech. Rev. Apr. 1999.
U.S. Appl. No. 60/553,945 to White.
Raillat et al., “Treatment of Iliac Artery Stenosis with the Wallstent Endoprosthesis.” AJR 154(3):613-6 (Mar. 1990).
Remadi et al., “Preliminary results of 130 aortic valve replacements with a new mechanical bileaflet prosthesis: the Edwards MIRA valve” Interactive Cardiovasc. and Thorac. Surg. 2, 80-83 (2003).
Rosch et al., “Gianturco-Rosch Expandable Z-Stents in the Treatment of Superior Vena Cava Syndrome.” Cardiovasc. Intervent. Radiol. 15: 319-327 (1992).
Schurink et al,. “Stent Attachment Site-related Endoleakage after Stent Graft Treatment: An in vitro study of the effects of graft size, stent type, and atherosclerotic wall changes.” J. Vasc. Surg., 30(4):658-67 (Oct. 1999).
Seminars in Interventional Cardiology, ed. P.W. Surruys, vol. 5 (2000).
Stanley et al., “Evaluation of Patient Selection Guidelines for Endoluminal AAA Repair With the Zenith Stent Graft: The Australasian Experience.” J. Endovasc. Ther. 8:457-464 (2001).
Steinhoff et al., “Tissue Engineering of Pulmonary Heart Valves on Allogenic Acellular Matrix Conduits.” Circulation, 102 [suppl. III]: III-50-III-55 (2000).
Tech., 287-292 (2000).
Textbook of Interventional Cardiology, 2d Ed., Chapter 75: Percutaneous Expandable Prosthetic Valves (1994).
Thompson et al., “Endoluminal stent grafting of the thoracic aorta: Initial experience with the Gore Excluder,” Journal of Vascular Surgery, 1163-70 (Jun. 2002).
VentureBeatProfiles, Claudio Argento, Jan. 7, 2010, http://venturebeatprofiles.com/person/profile/claudio-argento.
Vossoughi et al., Stent Graft Update (2000)—Kononov, Volodos, and Parodi and Palmaz Stents; Hemobahn Stent Graft.
White et al., “Endoleak as a Complication of Endoluminal Grafting of Abdominal Aortic Aneurysms: Classification, Incidence, Diagnosis, and Management.” J. Endovac. Surg., 4:152-168 (1997).
Related Publications (1)
Number Date Country
20160220360 A1 Aug 2016 US
Provisional Applications (1)
Number Date Country
62111449 Feb 2015 US